NZ710050B2 - Bace1 inhibitors - Google Patents

Abstract

The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease. treatment of e.g. Alzheimer's disease.

Description

BACE1 INHIBITORS Background Art Alzheimer’s disease (AD) is a neurodegenerative disorder of the central nervous system and the leading cause of a ssive dementia in the elderly population. Its al symptoms are impairment of memory, cognition, al and local orientation, judgment and reasoning but also severe emotional disturbances. There are currently no treatments available which can prevent the disease or its progression or stably reverse its clinical symptoms. AD has become a major health problem in all societies with high life expectancies and also a significant economic burden for their health s.

AD is characterized by 2 major pathologies in the central nervous system (CNS), the occurrence of d plaques and neurofibrillar tangles (Hardy et al., The amyloid hypothesis of Alzheimer's e: progress and problems on the road to therapeutics, Science. 2002 Jul 19;297(5580):353-6, Selkoe, Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease, Annu Rev Cell Biol. 1994;10:373-403). Both pathologies are also commonly observed in patients with Down’s syndrome (trisomy 21), which also develop AD-like symptoms in early life. Neurofibrillar tangles are intracellular aggregates of the microtubule-associated n tau (MAPT). Amyloid plaques occur in the extracellular space; their principal components are Aβ-peptides. The latter are a group of lytic fragments derived from the β-amyloid precursor n (APP) by a series of proteolytic cleavage steps. l forms of APP have been identified of which the most abundant are proteins of 695, 751 and 770 amino acids . They all arise from a single gene through differential splicing. The Aβ-peptides are derived from the same domain of the APP but differ at their N- and C-termini, the main species are of 40 and 42 amino-acid length. There are several lines of evidence which strongly suggest that aggregated Aβ-peptides are the essential molecules in the pathogenesis of AD: 1) amyloid plaques formed of Aβ-peptides are invariably part of the AD pathology; 2) Aβ- peptides are toxic for neurons; 3) in Familial mer’s Disease (FAD) the mutations in the disease genes APP, PSN1, PSN2 lead to increased levels of Aβ-peptides and early brain amyloidosis; 4) enic mice which s such FAD genes develop a pathology which bears many resemblances to the human disease. Aβ-peptides are produced from APP through the sequential action of 2 proteolytic enzymes termed - and -secretase. -Secretase cleaves first in the extracellular domain of APP approximately 28 amino acids outside of the membrane domain (TM) to produce a C-terminal fragment of APP containing the TM- and the cytoplasmatic domain (CTF). CTF  is the substrate for -secretase which cleaves at several adjacent positions within the TM to e the A peptides and the cytoplasmic fragment. The -secretase is a complex of at least 4 different proteins, its catalytic subunit is very likely a ilin n (PSEN1, PSEN2). The β-secretase (BACE1, Asp2; BACE stands for β-site APP-cleaving enzyme) is an aspartyl protease which is anchored into the membrane by a [Link] http://www.ncbi.nlm.nih.gov/pubmed?term=%22Barbiero%20L%22%5BAuthor%5D [Link] javascript:AL_get(this,%20'jour',%20'Exp%20Neurol.'); [Link] javascript:AL_get(this,%20'jour',%20'J%20Biol%20Chem.'); [Link] javascript:AL_get(this,%20'jour',%20'Clin%20Vaccine%20Immunol.'); [Link] javascript:AL_get(this,%20'jour',%20'Ann%20Neurol.'); [Link] javascript:AL_get(this,%20'jour',%20'Proc%20Natl%20Acad%20Sci%20U%20S%20A.'); [Link] javascript:AL_get(this,%20'jour',%20'Proc%20Natl%20Acad%20Sci%20U%20S%20A.'); [Link] javascript:AL_get(this,%20'jour',%20'Clin%20Cancer%20Res.'); [Link] javascript:AL_get(this,%20'jour',%20'Scand%20J%20Immunol.'); [Link] javascript:AL_get(this,%20'jour',%20'Mol%20Cell%20Biol.'); transmembrane domain (Vassar et al., Beta-secretase cleavage of Alzheimer's d precursor protein by the transmembrane aspartic protease BACE, Science. 1999 Oct 22;286(5440):735). It is expressed in many tissues of the human organism but its level is ally high in the CNS.

Genetic ablation of the BACE1 gene in mice has clearly shown that its activity is essential for the processing of APP which leads to the generation of Aβ-peptides, in the absence of BACE1 no tides are produced (Luo et al., Mice deficient in BACE1, the Alzheimer's betasecretase , have normal phenotype and abolished beta-amyloid generation, Nat Neurosci. 2001 Mar;4(3):231-2, Roberds et al., BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics, Hum Mol Genet. 2001 Jun 1;10(12):1317-24). Mice which have been genetically engineered to express the human APP gene and which form extensive amyloid plaques and Alzheimer’s disease like pathologies during aging fail to do so when β-secretase activity is reduced by genetic ablation of one of the BACE1 alleles (McConlogue et al., Partial reduction of BACE1 has dramatic s on mer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem. 2007 Sep 36):26326). It is thus presumed that inhibitors of BACE1 activity can be useful agents for therapeutic intervention in Alzheimer’s disease (AD).

Furthermore, the formation, or formation and deposition, of β-amyloid peptides in, on or around neurological tissue (e.g., the brain) are ted by the present compounds, i.e. inhibition of the Aβ-production from APP or an APP fragment. tors of BACE1 can in on be used to treat the following diseases: IBM (inclusion body myositis) (Vattemi G. et al., . 2001 Dec 8;358(9297):1962-4), Down’s Syndrome (Barbiero L. et al, Exp . 2003 Aug;182(2):335-45), Wilson’s Disease (Sugimoto I. et al., J Biol Chem. 2007 Nov 30;282(48):34896-903), e’s disease (Desnues B. et al., Clin Vaccine Immunol. 2006 Feb;13(2):170-8), SpinoCerebellar Ataxia 1 and SpinoCerebellar Ataxia 7 (Gatchel J.R. et al., Proc Natl Acad Sci U S A 2008 Jan 29;105(4):1291-6), Dermatomyositis (Greenberg S.A. et al., Ann Neurol. 2005 May;57(5):664- 78 and Greenberg S.A. et al., Neurol 2005 May;57(5):664-78), Kaposi Sarcoma (Lagos D. et al, Blood, 2007 Feb 15; 109(4):1550-8), Glioblastoma multiforme (E-MEXP-2576, http://www.ebi.ac.uk/microarray-as/aer/result?queryFor=PhysicalArrayDesign&aAccession=A- MEXP-258), Rheumatoid tis (Ungethuem U. et al, GSE2053), Amyotrophic l sclerosis (Koistinen H. et al., Muscle Nerve. 2006 Oct;34(4):444-50 and Li Q.X. et al, Aging Cell. 2006 Apr;5(2):153-65), Huntington’s Disease (Kim Y.J. et al., iol Dis. 2006 May;22(2):346-56. Epub 2006 Jan 19 and Hodges A. et al., Hum Mol Genet. 2006 Mar ;15(6):965-77. Epub 2006 Feb 8), Multiple Mieloma (Kihara Y. et al, Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21807-12), Malignant melanoma (Talantov D. et al, Clin Cancer Res. 2005 Oct 15;11(20):7234-42), Sjogren syndrome (Basset C. et al., Scand J Immunol. 2000 (3):307-11), Lupus matosus (Grewal P.K. et al, Mol Cell Biol. 2006, Jul;26(13):4970-81), Macrophagic myofasciitis, le idiopathic arthritis, granulomatous arthritis, Breast cancer nd M. et al, Cancer Res. 2008 Jan 15;68(2):388-94 and Kondoh K. et al., Breast Cancer Res Treat. 2003 Mar;78(1):37-44), intestinal diseases (Hoffmeister A. et al, JOP. 2009 Sep 4;10(5):501-6), Autoimmune/inflammatory diseases (Woodard-Grice A.V. et al., J Biol Chem. 2008 Sep 26;283(39):26364-73. Epub 2008 Jul 23), Rheumatoid Arthritis (Toegel S. et al, Osteoarthritis Cartilage. 2010 Feb;18(2):240-8. Epub 2009 Sep 22), Inflammatory reactions (Lichtenthaler S.F. et al., J Biol Chem. 2003 Dec 5;278(49):48713-9.

Epub 2003 Sep 24), Arterial Thrombosis (Merten M. et al., Z Kardiol. 2004 Nov;93(11):855-63), Cardiovascular diseases such as Myocardial infarction and stroke (Maugeri N. et al., Srp Arh Celok Lek. 2010 Jan;138 Suppl 1:50-2) and Graves disease (Kiljański J. et al, Thyroid. 2005 Jul;15(7):645-52).

WO2013027188 describe 2-Amino(pyridinyl)-5,6-dihydro-4H-1,3-oxazine derivatives and their use as BACE-1 and/or BACE- 2 inhibitors, EP2511268 and WO012147763 describe oxazine derivatives as BACE1 tors.

The present invention provides novel compounds of formula I, their manufacture, medicaments based on a compound in accordance with the invention and their tion as well as the use of compounds of formula I in the control or prevention of illnesses such as Alzheimer’s disease. Furthermore the use of nds of a I in the treatment of amyotrophic lateral sclerosis (ALS), arterial thrombosis, autoimmune/inflammatory diseases, cancer such as breast , cardiovascular diseases such as myocardial infarction and stroke, dermatomyositis, Down’s Syndrome, gastrointestinal diseases, Glioblastoma multiforme, Graves Disease, Huntington’s e, inclusion body myositis (IBM), inflammatory ons, Kaposi Sarcoma, Kostmann Disease, lupus erythematosus, macrophagic myofasciitis, juvenile idiopathic arthritis, granulomatous arthritis, malignant melanoma, multiple mieloma, rheumatoid arthritis, n syndrome, SpinoCerebellar Ataxia 1, SpinoCerebellar Ataxia 7, Whipple’s Disease and Wilson’s Disease. The novel compounds of formula I have improved pharmacological properties.

Field of the ion The present invention provides Fluoromethyl-5,6-dihydro-4H-[1,3]oxazinylamines having BACE1 inhibitory properties, their manufacture, pharmaceutical compositions ning them and their use as therapeutically active substances.

Summary of the ion The present invention provides a compound of formula I, H N O R5 H N R1 N N R4 wherein the substituents and variables are as described in the claims, or a pharmaceutically acceptable salt thereof.

The t nds have Asp2 (β-secretase, BACE1 or Memapsin-2) inhibitory activity and may therefore be used in the eutic and/or prophylactic treatment of diseases and disorders characterized by elevated oid levels and/or β-amyloid oligomers and/or β-amyloid plaques and further deposits, particularly Alzheimer's disease.

More specifically, in a first aspect, the present invention provides a compound of a I, H N O R5 H N R1 N N R4 wherein R1 is heteroaryl substituted by 1-2 substituents individually selected from amino, cyano, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy and C1alkyl; R2 is F; R3 is ; R4 is fluoro; R5 is trifluoromethyl; or pharmaceutically acceptable salts thereof.

In a second aspect, the present invention provides a compound of formula I, which is of formula Ia-1 H N O CF 2 3 H N R1 N N R4 F Ia-1 wherein R1 is heteroaryl substituted by 1-2 substituents individually selected from amino, cyano, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy and C1alkyl; R3 is methyl; R4 is fluoro; or pharmaceutically acceptable salts thereof.

In a r aspect, the present invention provides a compound of formula I according to the first or second aspect, or a ceutically acceptable salt thereof, for use as a therapeutically active substance, for use as therapeutically active substance for the therapeutic and/or lactic treatment of diseases and disorders terized by elevated β-amyloid levels and/or β-amyloid oligomers and/or β-amyloid plaques and further deposits or Alzheimer's disease, or for use as therapeutically active substance for the therapeutic and/or lactic treatment of amyotrophic lateral sclerosis (ALS), arterial osis, autoimmune/inflammatory diseases, cancer such as breast cancer, cardiovascular diseases such as myocardial infarction and stroke, dermatomyositis, Down’s Syndrome, gastrointestinal diseases, Glioblastoma multiforme, Graves Disease, Huntington’s Disease, inclusion body myositis (IBM), inflammatory reactions, Kaposi Sarcoma, Kostmann Disease, lupus matosus, macrophagic myofasciitis, juvenile idiopathic arthritis, granulomatous arthritis, ant melanoma, multiple mieloma, rheumatoid arthritis, Sjogren syndrome, SpinoCerebellar Ataxia 1, erebellar Ataxia 7, Whipple’s Disease or Wilson’s Disease.

In a yet further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula I according to the first or second aspect, or a pharmaceutically acceptable salt thereof, and a pharmaceutically able carrier and/or a pharmaceutically acceptable auxiliary nce.

In r aspect, the t invention provides use of a compound of formula I according to the first or second aspect, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the therapeutic and/or prophylactic ent of Alzheimer's disease.

Detailed Description of the Invention The present invention es a nd of formula I and their pharmaceutically acceptable salts thereof, the preparation of the above mentioned compounds, medicaments containing them and their manufacture as well as the use of the above mentioned compounds in the eutic and/or prophylactic treatment of diseases and disorders which are associated with inhibition of BACE1, such as Alzheimer’s disease. Furthermore, the formation, or formation and deposition, of β-amyloid plaques in, on or around neurological tissue (e.g., the brain) are inhibited by the present compounds by inhibiting the Aβ production from APP or an APP fragment.

The following definitions of the general terms used in the present description apply irrespectively of whether the terms in question appear alone or in combination with other groups.

Unless otherwise stated, the following terms used in this Application, including the specification and , have the definitions given below. It must be noted that, as used in the specification and the appended claims, the ar forms "a", "an," and "the" include plural referents unless the context clearly dictates otherwise.

The term "C1alkyl", alone or in combination with other groups, stands for a hydrocarbon radical which may be linear or ed, with single or multiple branching, wherein the alkyl group in general comprises 1 to 6 carbon atoms, for example, methyl (Me), ethyl (Et), propyl, isopropyl (i-propyl), n-butyl, i-butyl (isobutyl), 2-butyl (sec-butyl), t-butyl (tert-butyl), isopentyl, 2-ethyl-propyl hyl-propyl), 1,2-dimethyl-propyl and the like. Particular "C1alkyl" are "C1alkyl". Specific groups are methyl and ethyl. Most specific is methyl.

The term "halogen-C1alkyl", alone or in combination with other groups, refers to C1 alkyl as d , which is substituted by one or multiple halogen, particularly 1-5 halogen, more particularly 1-3 halogen. Particular halogen is fluoro. Particular "halogen-C1alkyl" is fluoro-C1alkyl and a particular en-C1alkyl" is fluoro-C1alkyl. Examples are trifluoromethyl, difluoromethyl, fluoromethyl and the like. Specific groups are difluoromethyl and oromethyl.

The term "cyano-C1alkyl", alone or in combination with other groups, refers to C1 alkyl as defined herein, which is substituted by one or multiple cyano, particularly 1 cyano.

Examples are cyanomethyl, cyanoethyl and the like.

The term "C1alkoxy-C1alkyl", alone or in combination with other groups, refers to C1- 6-alkyl as defined herein, which is tuted by one or multiple C1alkoxy, as defined herein, particularly 1 C1alkoxy. Particular "C1alkoxy-C1alkyl" is methoxy-C1alkyl. Examples are methoxymethyl, methoxyethyl and the like.

The term "cyano", alone or in ation with other groups, refers to N≡C-(NC-).

The term "halogen", alone or in combination with other , s chloro (Cl), iodo (I), fluoro (F) and bromo (Br). Particular "halogen" is Cl and F. A ic group is F.

The term "heteroaryl", alone or in combination with other groups, refers to an aromatic carbocyclic group of having a single 4 to 8 membered ring, in particular 5 to 8, or multiple sed rings sing 6 to 14, in particular 6 to 10 ring atoms and containing 1, 2 or 3 heteroatoms individually selected from N, O and S, in particular 1N or 2N, in which group at least one heterocyclic ring is aromatic. Examples of "heteroaryl" include benzofuryl, benzoimidazolyl, 1H-benzoimidazolyl, benzooxazinyl, benzoxazolyl, benzothiazinyl, benzothiazolyl, benzothienyl, benzotriazolyl, furyl, imidazolyl, indazolyl, 1H-indazolyl, indolyl, isoquinolinyl, isothiazolyl, isoxazolyl, yl, pyrazinyl, pyrazolyl (pyrazyl), 1H-pyrazolyl, pyrazolo[1,5-a]pyridinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, inyl, tetrazolyl, thiazolyl, thienyl, triazolyl, 6,7-dihydro-5H-[1]pyrindinyl and the like. Particular "heteroaryl" are pyridinyl, pyrazinyl and 1H-pyrazolyl, as well as oxazolyl and 1H-pyrazolyl. Specific oaryl" are pyridinyl, nyl and 1H-pyrazolyl.

The term "C1alkoxy", alone or in combination with other groups, stands for an -O-C1 alkyl radical which may be linear or branched, with single or multiple branching, wherein the alkyl group in general comprises 1 to 6 carbon atoms, for example, methoxy (OMe, MeO), ethoxy (OEt), propoxy, isopropoxy (i-propoxy), n-butoxy, i-butoxy (iso-butoxy), 2-butoxy (secbutoxy ), t-butoxy (tert-butoxy), isopentyloxy (i-pentyloxy) and the like. ular "C1alkoxy" are groups with 1 to 4 carbon atoms. Specific is methoxy.

The term "halogen-C1alkoxy", alone or in combination with other groups, refers to C1 alkoxy as d herein, which is substituted by one or multiple halogens, in ular .

Particular "halogen-C1alkoxy" are fluoro-C1alkoxy. Specific "halogen-C1alkoxy" is trifluoromethoxy.

The term "C2alkynyl-C1alkoxy", alone or in combination with other groups, refers to C1alkoxy as defined herein, which is substituted by one or multiple C2alkynyl as defined herein, in particular 1 C2alkynyl.

The term "C2alkynyl", alone or in ation with other groups, denotes a monovalent linear or branched ted hydrocarbon group of 2 to 6 carbon atoms, in particular from 2 to 4 carbon atoms, and comprising one, two or three triple bonds. es of C2alkynyl include ethynyl, propynyl, and n-butynyl.

The term "aryl" denotes a monovalent aromatic carbocyclic mono- or bicyclic ring system comprising 6 to 10 carbon ring atoms. Examples of aryl moieties include phenyl and naphthyl.

Specific "aryl" is phenyl.

The term "pharmaceutically acceptable salts" refers to salts that are le for use in contact with the tissues of humans and animals. Examples of suitable salts with inorganic and organic acids are, but are not limited to acetic acid, citric acid, formic acid, fumaric acid, hloric acid, lactic acid, maleic acid, malic acid, methane-sulfonic acid, nitric acid, phosphoric acid, p-toluenesulphonic acid, succinic acid, sulfuric acid (sulphuric acid), tartaric acid, trifluoroacetic acid and the like. Particular acids are formic acid, trifluoroacetic acid and hydrochloric acid. Specific acids are hydrochloric acid, oroacetic acid and fumaric acid.

The terms "pharmaceutically acceptable carrier" and "pharmaceutically acceptable auxiliary substance" refer to carriers and auxiliary substances such as diluents or excipients that are compatible with the other ients of the formulation.

The term "pharmaceutical composition" encompasses a product comprising specified ingredients in pre-determined amounts or proportions, as well as any product that results, directly or indirectly, from combining specified ingredients in specified amounts. Particularly it encompasses a product comprising one or more active ingredients, and an optional carrier sing inert ingredients, as well as any product that results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.

The term itor" denotes a compound which es with, reduces or prevents the binding of a particular ligand to particular receptor or which reduces or prevents the tion of the function of a particular protein.

The term "half maximal inhibitory concentration" (IC50) denotes the tration of a particular nd required for obtaining 50% inhibition of a biological process in vitro. IC50 values can be converted logarithmically to pIC50 values (-log IC50), in which higher values indicate exponentially greater potency. The IC50 value is not an absolute value but depends on experimental conditions e.g. concentrations employed. The IC50 value can be converted to an absolute tion constant (Ki) using the Cheng-Prusoff equation (Biochem. Pharmacol. (1973) 22:3099). The term "inhibition constant" (Ki) denotes the absolute binding affinity of a particular inhibitor to a receptor. It is measured using competition binding assays and is equal to the concentration where the particular inhibitor would occupy 50% of the receptors if no competing ligand (e.g. a radioligand) was present. Ki values can be converted logarithmically to pKi values (-log Ki), in which higher values indicate exponentially greater potency.

"Therapeutically effective amount" means an amount of a compound that, when stered to a subject for treating a disease state, is sufficient to effect such treatment for the disease state. The "therapeutically effective amount" will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the ing medical or veterinary practitioner, and other factors.

The term "as defined herein" and "as described herein" when referring to a le incorporates by reference the broad definition of the variable as well as ularly, more particularly and most particularly definitions, if any.

The terms "treating", cting" and "reacting" when referring to a chemical reaction means adding or mixing two or more ts under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the e which ultimately leads to the formation of the indicated and/or the desired product.

The term "protecting group" denotes the group which ively blocks a reactive site in a multifunctional nd such that a chemical reaction can be carried out selectively at r unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry.

Protecting groups can be removed at the appropriate point. ary ting groups are amino-protecting groups, carboxy-protecting groups or hydroxy-protecting groups. The term "amino protecting group" (here also X) denotes groups intended to protect an amino group and includes benzyl, benzyloxycarbonyl (carbobenzyloxy, CBZ), 9-Fluorenylmethyloxycarbonyl (FMOC), p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, tert-butoxycarbonyl (BOC), and trifluoroacetyl. Further examples of these groups are found in T. W. Greene and P. G. M.

Wuts, "Protective Groups in Organic Synthesis", 2nd ed., John Wiley & Sons, Inc., New York, NY, 1991, chapter 7; E. Haslam, "Protective Groups in Organic Chemistry", J. G. W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapter 5, and T.W. Greene, "Protective Groups in Organic Synthesis", John Wiley and Sons, New York, NY, 1981. The term "protected amino group" refers to an amino group substituted by an amino-protecting groups. ular amino- protecting groups are tert-butoxycarbonyl group and dimethoxytrityl.

The term "leaving group" denotes the group with the meaning tionally associated with it in synthetic organic chemistry, i.e., an atom or group displaceable under substitution reaction conditions. Examples of leaving groups include halogen, in particular bromo, alkane- or arylenesulfonyloxy, such as methanesulfonyloxy, ethanesulfonyloxy, thiomethyl, benzenesulfonyloxy, tosyloxy, dihalophosphinoyloxy, optionally substituted benzyloxy, isopropyloxy, and acyloxy.

The term "aromatic" denotes the conventional idea of aromaticity as defined in the literature, in particular in IUPAC - Compendium of Chemical Terminology, 2nd, A. D.

McNaught & A. Wilkinson (Eds). ell Scientific Publications, Oxford .

The term "pharmaceutically acceptable excipient" s any ingredient having no therapeutic activity and being non-toxic such as disintegrators, binders, s, solvents, buffers, tonicity , stabilizers, antioxidants, surfactants or lubricants used in formulating pharmaceutical products.

Whenever a chiral carbon is t in a chemical structure, it is intended that all stereoisomers associated with that chiral carbon are encompassed by the structure as pure stereoisomers as well as mixtures thereof.

The invention also provides pharmaceutical compositions and methods of preparing the aforementioned compounds. Methods of using the aforementioned compounds are bed All separate embodiments may be combined.

One embodiment provides a compound of formula I, H N O R5 H N R1 N N R4 wherein R1 is selected from the group consisting of i) aryl, ii) aryl substituted by 1-4 substituents individually selected from amino, cyano, cyano-C1alkyl, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy, C1 alkoxy-C1alkyl, C2alkynyl-C1alkoxy, C2alkynyl and lkyl, iii) heteroaryl, and iv) heteroaryl substituted by 1-4 substituents individually selected from amino, cyano, cyano-C1alkyl, halogen, n-C1alkoxy, halogen-C1alkyl, C1alkoxy, C1 alkoxy-C1alkyl, lkynyl-C1alkoxy, C2alkynyl and C1alkyl; R2 is selected from the group consisting of i) hydrogen, ii) C1alkyl, and iii) halogen; R3 is selected from the group consisting of i) C1alkyl, and ii) halogen-C1alkyl, R4 is selected from the group ting of i) n, and ii) hydrogen, R5 is halogen-C1alkyl; or pharmaceutically acceptable salts thereof.

A certain embodiment provides a compound of formula Ia, H N O R5 H N R1 N N R4 wherein R1 is selected from the group consisting of i) aryl, ii) aryl substituted by 1-2 substituents individually selected from amino, cyano, cyano-C1alkyl, n, n-C1alkoxy, halogen-C1alkyl, C1alkoxy, C1 alkoxy-C1alkyl, C2alkynyl-C1alkoxy, C2alkynyl and C1alkyl, iii) heteroaryl, and iv) heteroaryl substituted by 1-2 substituents individually ed from amino, cyano, cyano-C1alkyl, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy, C1 alkoxy-C1alkyl, C2alkynyl-C1alkoxy, lkynyl and C1alkyl; R2 is selected from the group ting of i) hydrogen, ii) C1alkyl, and iii) halogen; R3 is selected from the group consisting of i) C1alkyl, and ii) halogen-C1alkyl, R4 is selected from the group consisting of i) halogen, and ii) hydrogen, R5 is halogen-C1alkyl; or pharmaceutically acceptable salts thereof.

A certain embodiment provides a compound of formula Ic, H N O R5 H N R1 N N R4 Ic wherein R1 is selected from the group consisting of i) aryl, ii) aryl substituted by 1-4 substituents individually selected from amino, cyano, cyano-C1alkyl, n, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy, C1 alkoxy-C1alkyl, C2alkynyl-C1alkoxy, C2alkynyl and C1alkyl, iii) heteroaryl, and iv) heteroaryl substituted by 1-4 substituents individually selected from amino, cyano, cyano-C1alkyl, halogen, halogen-C1alkoxy, halogen-C1alkyl, lkoxy, C1 alkoxy-C1alkyl, C2alkynyl-C1alkoxy, C2alkynyl and C1alkyl; R2 is selected from the group consisting of i) hydrogen, ii) C1alkyl, and iii) n; R3 is selected from the group consisting of i) C1alkyl, and ii) halogen-C1alkyl, R4 is selected from the group consisting of i) n, and ii) hydrogen, R5 is halogen-C1alkyl; or pharmaceutically acceptable salts thereof.

A n embodiment provides a compound of formula Id, H N O R5 H N R1 N N R4 wherein R1 is selected from the group consisting of i) aryl, ii) aryl substituted by 1-4 substituents individually selected from amino, cyano, cyano-C1alkyl, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy, C1 alkoxy-C1alkyl, C2alkynyl-C1alkoxy, C2alkynyl and C1alkyl, iii) aryl, and iv) heteroaryl substituted by 1-4 substituents individually selected from amino, cyano, cyano-C1alkyl, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy, C1 alkoxy-C1alkyl, lkynyl-C1alkoxy, C2alkynyl and C1alkyl; R2 is selected from the group ting of i) hydrogen, ii) C1alkyl, and iii) halogen; R3 is selected from the group consisting of i) C1alkyl, and ii) halogen-C1alkyl, R4 is selected from the group consisting of i) n, and ii) hydrogen, R5 is halogen-C1alkyl; or pharmaceutically acceptable salts thereof.

A certain embodiment provides a compound of formula Ia-1, H N O CF 2 3 H N R1 N N R4 R2 Ia-1 wherein R1 is selected from the group ting of i) aryl, ii) aryl substituted by 1-2 substituents individually selected from amino, cyano, cyano-C1alkyl, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy, C1 alkoxy-C1alkyl, C2alkynyl-C1alkoxy, C2alkynyl and C1alkyl, iii) heteroaryl, and iv) heteroaryl substituted by 1-2 tuents individually selected from amino, cyano, cyano-C1alkyl, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy, C1 alkoxy-C1alkyl, C2alkynyl-C1alkoxy, C2alkynyl and C1alkyl; and R3 is selected from the group consisting of i) C1alkyl, and ii) halogen-C1alkyl, R4 is selected from the group consisting of i) halogen, and ii) hydrogen, or ceutically able salts thereof.

A certain embodiment provides a compound of a I, wherein R1 is heteroaryl substituted by 1-2 substituents individually selected from cyano, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy, and lkyl; R2 is hydrogen; R3 is C1alkyl; R4 is selected from the group consisting of i) halogen, and ii) hydrogen, and R5 is halogen-C1alkyl.

A certain embodiment provides a compound of formula I, wherein R1 is aryl substituted by 1-2 substituents individually selected from cyano, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy, and C1alkyl; R2 is hydrogen; R3 is C1alkyl; R4 is hydrogen; and R5 is halogen-C1alkyl.

A certain embodiment of the invention provides a compound of formula I as described herein, wherein R1 is heteroaryl substituted by 1-2 substituents individually selected from amino and cyano.

A certain embodiment of the invention provides a compound of formula I as described herein, wherein R1 is heteroaryl substituted by 1-2 substituents individually selected from cyano, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy and C1alkyl.

A n embodiment of the ion provides a compound of formula I as described , wherein R1 is pyridinyl, 1H-pyrazolyl or pyrazinyl, each substituted by 1-2 tuents individually selected from cyano, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy and C1alkyl.

A certain embodiment of the invention provides a compound of formula I as described herein, wherein R1 is 3,5-dichloro-pyridinyl, 3-chlorocyano-pyridinyl, 3-chloro trifluoromethyl-pyridinyl, 4-chloro(difluoromethyl)-1H-pyrazolyl, 5-(difluoromethyl)- pyrazinyl, 5-(fluoromethoxy)pyridinyl, 5-cyanomethyl-pyridinyl, 5-cyano-pyridinyl, 5- methoxy-pyrazinyl or 5-methoxy-pyridinyl.

A certain embodiment of the invention provides a compound of a I as described herein, wherein er R1 is aryl it is pyridinyl, azolyl or nyl.

A certain embodiment of the invention provides a nd of formula I as described herein, wherein whenever R1 is heteroaryl it is pyridinyl or pyrazinyl.

A certain embodiment of the invention provides a compound of formula I as described herein, wherein whenever R1 is heteroaryl it is pyridinyl.

A certain embodiment of the invention provides a compound of a I as described herein, wherein R1 is 5-cyano-pyridineyl.

A certain embodiment of the invention provides a compound of formula I as bed herein, wherein whenever R1 is heteroaryl it is pyrazinyl.

A certain embodiment of the invention provides a compound of formula I as described herein, wherein er R1 is heteroaryl it is 3-amino-pyrazineyl.

A certain embodiment provides a compound of formula I as described herein, wherein R2 is halogen.

A certain embodiment of the invention provides a compound of a I as bed herein, n R2 is F.

A certain embodiment provides a compound of formula I as described herein, wherein R3 is C1alkyl.

A n embodiment of the invention provides a compound of formula I as described herein, wherein R3 is methyl.

A certain embodiment provides a compound of formula I as described herein, wherein R4 is A certain embodiment of the invention provides a nd of formula I as described herein, wherein R4 is F.

A certain embodiment provides a nd of formula I as described herein, wherein R4 is hydrogen.

A certain embodiment es a compound of formula I as described herein, wherein R5 is -C1alkyl.

A certain embodiment of the invention provides a compound of formula I as described herein, wherein R5 is oromethyl.

A certain embodiment provides a compound of formula I as described herein, that is selected from the group ting of N-(6-((4R,5R,6R)aminofluoromethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin yl)fluoropyridinyl)cyanopicolinamide, N-(6-((4R,5R,6S)aminofluoromethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin yl)fluoropyridinyl)cyanopicolinamide, N-(6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) fluoropyridinyl)cyanopicolinamide, N-(6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) fluoropyridinyl)chlorocyanopicolinamide, N-(6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) fluoropyridinyl)chloro(trifluoromethyl)picolinamide trifluoroacetate, (4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) fluoropyridinyl)methoxypyrazinecarboxamide 2,2,2-trifluoroacetate, N-(6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) fluoropyridinyl)cyanomethylpicolinamide 2,2,2-trifluoroacetate, N-(6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) pyridinyl)methoxypicolinamide 2,2,2-trifluoroacetate, N-(6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) fluoropyridinyl)chloro(difluoromethyl)-1H-pyrazolecarboxamide 2,2,2- trifluoroacetate, N-(6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) fluoropyridinyl)(difluoromethyl)pyrazinecarboxamide 2,2,2-trifluoroacetate, N-(6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) fluoropyridinyl)-3,5-dichloropicolinamide 2,2,2-trifluoroacetate, N-(6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) pyridinyl)(fluoromethoxy)picolinamide 2,2,2-trifluoroacetate, and N-(6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) chloropyridinyl)cyanopicolinamide, or pharmaceutically acceptable salts thereof.

A certain embodiment provides a compound of formula I as described herein, which is N- (6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl) fluoropyridinyl)cyanopicolinamide or a pharmaceutically acceptable salt thereof.

A certain embodiment of the invention relates to process for preparing a nd of formula I as defined herein, which process comprises reacting a compound of formula XI’ with a compound of a XII’ to a compound of formula I HN O R5 H N N R4 2 R1 OH XI' XII' , wherein R1, R2, R3, R4 and R5 are as defined herein and X is an amino protecting group.

A certain embodiment of the invention provides a compound of formula I as described herein, whenever ed by a process as defined above.

A certain embodiment of the invention provides a nd of a I as described herein for use as therapeutically active substance.

A certain embodiment of the ion provides a compound of formula I as described herein for the use as inhibitor of BACE1 activity.

A certain embodiment of the ion provides a compound of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or lactic treatment of diseases and disorders characterized by elevated β-amyloid levels and/or β-amyloid ers and/or β-amyloid plaques and further deposits or Alzheimer's disease.

A certain embodiment of the invention provides a compound of formula I as described herein for the use as therapeutically active substance for the eutic and/or prophylactic treatment of Alzheimer's disease.

A certain embodiment of the invention provides a nd of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of amyotrophic lateral sis (ALS), arterial thrombosis, autoimmune/inflammatory diseases, cancer such as breast cancer, vascular diseases such as myocardial infarction and stroke, dermatomyositis, Down’s me, gastrointestinal diseases, Glioblastoma multiforme, Graves Disease, Huntington’s Disease, inclusion body myositis (IBM), inflammatory reactions, Kaposi Sarcoma, Kostmann Disease, lupus erythematosus, macrophagic myofasciitis, juvenile idiopathic arthritis, granulomatous arthritis, malignant melanoma, multiple mieloma, rheumatoid arthritis, Sjogren syndrome, SpinoCerebellar Ataxia 1, SpinoCerebellar Ataxia 7, Whipple’s Disease or Wilson’s Disease.

A certain embodiment of the invention provides a pharmaceutical ition sing a compound of formula I as described herein and a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable auxiliary substance.

A certain embodiment of the invention provides the use of a nd of formula I as described herein for the manufacture of a medicament for the use in inhibition of BACE1 activity.

A n embodiment of the invention provides the use of a compound of a I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated β-amyloid levels and/or β-amyloid oligomers and/or β-amyloid plaques and further deposits or Alzheimer's disease.

A n embodiment of the invention es the use of a nd of formula I as described herein for the manufacture of a ment for the therapeutic and/or prophylactic treatment of Alzheimer's disease.

A certain embodiment of the ion provides the use of a compound of formula I as described herein for the cture of a medicament for the therapeutic and/or prophylactic treatment of amyotrophic lateral sclerosis (ALS), arterial thrombosis, autoimmune/inflammatory diseases, cancer such as breast cancer, cardiovascular diseases such as myocardial infarction and stroke, dermatomyositis, Down’s Syndrome, gastrointestinal diseases, astoma multiforme, Graves Disease, Huntington’s Disease, inclusion body myositis (IBM), inflammatory reactions, Kaposi Sarcoma, Kostmann Disease, lupus erythematosus, macrophagic myofasciitis, juvenile idiopathic arthritis, granulomatous arthritis, malignant ma, multiple mieloma, rheumatoid arthritis, Sjogren syndrome, SpinoCerebellar Ataxia 1, SpinoCerebellar Ataxia 7, Whipple’s Disease or Wilson’s Disease.

A certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic ent of mer's e.

A certain embodiment of the ion provides a compound of formula I as described herein for the use in inhibition of BACE1 activity.

A certain embodiment of the invention provides a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated β-amyloid levels and/or β-amyloid oligomers and/or β-amyloid plaques and further deposits or Alzheimer's disease.

A certain embodiment of the invention provides a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of Alzheimer's disease.

A certain embodiment of the ion provides a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of ophic lateral sclerosis (ALS), arterial thrombosis, autoimmune/inflammatory diseases, cancer such as breast , cardiovascular diseases such as myocardial infarction and stroke, dermatomyositis, Down’s Syndrome, gastrointestinal diseases, Glioblastoma multiforme, Graves Disease, Huntington’s Disease, inclusion body myositis (IBM), inflammatory reactions, Kaposi Sarcoma, Kostmann Disease, lupus erythematosus, macrophagic myofasciitis, le idiopathic arthritis, granulomatous arthritis, malignant melanoma, multiple a, rheumatoid arthritis, Sjogren syndrome, SpinoCerebellar Ataxia 1, SpinoCerebellar Ataxia 7, Whipple’s e or Wilson’s Disease.

Described herein is a method for the use in tion of BACE1 activity, particularly for the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated β-amyloid levels and/or β-amyloid oligomers and/or β-amyloid plaques and further deposits or Alzheimer's disease, which method comprises administering nd of formula I as described herein to a human being or animal.

Described herein is a method for the use in the therapeutic and/or prophylactic treatment of Alzheimer's disease, which method comprises administering a nd of formula I as described herein to a human being or animal.

Described herein is a method for the use in the therapeutic and/or prophylactic treatment of amyotrophic lateral sclerosis (ALS), al thrombosis, mune/inflammatory diseases, cancer such as breast , cardiovascular diseases such as myocardial infarction and stroke, dermatomyositis, Down’s Syndrome, gastrointestinal diseases, Glioblastoma multiforme, Graves Disease, Huntington’s Disease, inclusion body myositis (IBM), inflammatory ons, Kaposi Sarcoma, Kostmann Disease, lupus erythematosus, macrophagic myofasciitis, juvenile idiopathic arthritis, granulomatous arthritis, malignant melanoma, multiple mieloma, rheumatoid arthritis, Sjogren syndrome, erebellar Ataxia 1, erebellar Ataxia 7, Whipple’s Disease or Wilson’s Disease, which method comprises administering a compound of a I as described herein to a human being or animal.

Furthermore, the invention includes all optical isomers, i.e. diastereoisomers, reomeric mixtures, racemic mixtures, all their corresponding enantiomers and/or tautomers as well as their solvates of the compounds of formula I.

The skilled person in the art will recognize that the compounds of formula I can exist in tautomeric form HN O R5 H HN R1 N N R4 All tautomeric forms are encompassed in the present invention.

The compounds of a I may contain one or more asymmetric s and can therefore occur as racemates, racemic es, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within this invention. The present invention is meant to encompass all such isomeric forms of these compounds. The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by riate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a t containing an asymmetric center of known te configuration. If desired, racemic es of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography. Stereoisomers of compounds of formula I are nds of formula Ia or nds of formula Ib, in particular nds of a Ia, wherein the residues have the meaning as described in any of the embodiments.

H N O R5 2 H N O R5 H N H R1 N N N R4 R1 N N R4 R3 R3 O O R2 R2 Ia Ib In the embodiments, where optically pure enantiomers are provided, optically pure enantiomer means that the compound contains > 90 % of the desired isomer by weight, particularly > 95 % of the desired isomer by weight, or more ularly > 99 % of the desired isomer by weight, said weight percent based upon the total weight of the isomer(s) of the compound. Chirally pure or chirally enriched compounds may be prepared by chirally selective synthesis or by tion of enantiomers. The separation of enantiomers may be carried out on the final t or alternatively on a le intermediate.

The compounds of formula I may be prepared in ance with the following schemes.

The starting material is commercially available or may be prepared in accordance with known methods. Any previously defined residues and les will continue to have the previously defined meaning unless otherwise indicated.

The compounds of formula I can be prepared through a number of synthetic routes for example as illustrated in schemes 1 and 2. The preparation of compounds of formula I of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the compounds of the invention are shown in the following scheme 1. The skills required for carrying out the reaction and purification of the resulting products are known to those skilled in the art. The substituents and indices used in the following description of the processes have the significance given herein before unless ted to the contrary.

In more detail, the compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. The reaction sequence is not limited to the one displayed in schemes described below, however, depending on the starting materials and their respective reactivity the sequence of on steps can be freely altered. Starting materials are either commercially ble or can be prepared by methods analogous to the s given below, by methods bed in nces cited in the description or in the examples, or by methods known in the art.

The compounds of formula I described in the scheme 1 can be isolated and purified by methods known to those skilled in the art, such as but not limited to ion exchange chromatography, solid phase extraction, liquid-liquid extraction, silica chromatography, llization and preparative HPLC.

In more detail, compounds of formula I according to the t invention can be prepared by the methods and procedures given below. Some typical ures for the preparation of compounds of formula I are illustrated in scheme 1.

A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13 A14 A15 I' Scheme 1: Synthesis of compounds I’ Non cial ketones of general formula A3 can be synthesized by routes such as depicted in scheme 1 or by other routes known to those skilled in the art. Weinreb amides of formula A2 can be obtained by standard condensation reactions of the acids of formula A1 with N,O-dimethylhydroxylamine or by the intermediate formation of the acyl chloride of acids of formula A1 using an agent such as oxalyl chloride or l chloride using standard conditions such as ylamine/dichloromethane. The amides of formula A2 can be reacted with organometallics such as methylmagnesium bromide (for R3 = Me) in inert aprotic solvents such as tetrahydrofuran or diethyl ether to yield the desired ketones of formula A3.

Intermediate amino ls of formula A9 can be prepared in an enantioselective manner as follows: ic s of formula A3 can be converted into the sulfinyl imine of general a A4 in y to T.P. Tang & J.A. Ellman, J. Org. Chem. 1999, 64, 12, by condensation of the aryl ketone group and a sulfinamide, e.g. an alkyl amide, in this case most particular (R)-(+)-tert-butylsulfinamide in the presence of a Lewis acid such as e.g. a titanium(IV)alkoxide, more particular titanium(IV)ethoxide in a solvent such as an ether, e.g. diethyl ether or more particular tetrahydrofuran, at temperatures between 23 °C and 70 °C.

The conversion of the sulfinyl imine A4 to the sulfinamide ester A5 proceeds stereoselectively by the chiral directing group as described by Tang & Ellman. The sulfinyl imine A4 can be reacted with a titanium enolate generated from e.g. an alkyl acetate, particular ethyl acetate, LDA and chlorotriisopropoxytitanium at low temperature, particular at –78 °C in a solvent such as an ether, e.g. diethyl ether or more particular THF. Alternatively sulfinamide ester A5 can be produced from sulfinyl imine A4 by Reformatsky reaction of a bromoacetic ester derivative and zinc dust, optionally in the presence of copper(I) chloride, in a solvent such as an ether, e.g. diethyl ether or more particular THF, at temperatures from 0 to 70 °C, particular at 5 to 10 °C.

Chiral sulfinamide ester A5 can be d to the chiral l A6 by the ion of the ethyl ester with an alkali hydride, particular lithium borohydride or lithium aluminum hydride in a solvent such as an ether, e.g. diethyl ether or more particular THF, at temperatures between 0 °C and 50 °C, particular at 23 °C.

Oxidation of the chiral alcohol A6 to the chiral aldehyde A7 can be achieved by various oxidation methods known to those skilled in the art. DMSO based oxidations, such as the Swern- Moffat oxidation using DMSO, oxalyl chloride and an amine base such as triethylamine or diisopropylethylamine or the Parikh-Doering oxidation using DMSO, sulfur trioxide-pyridine- complex and an amine base such as triethylamine or diisopropylethylamine are particular methods.

The chiral alcohol A8 can be produced by addition of hyl(trifluoromethyl)silane (Ruppert-Prakash reagent) to the chiral aldehyde A7 in the presence of a catalytic amount of a fluoride source such as tetrabutylammonium fluoride or tetramethylammonium fluoride in a solvent such as an ether, e.g. l ether or more particular THF, at temperatures from –40 to 23 °C, ular at –20 to 0 °C. Further addition of a super-stoichiometric amount of tetrabutylammonium fluoride cleaves the lly produced trimethylsilylether of chiral alcohol A8 to the free hydroxyl group. The reaction produces variable ratios of chiral alcohol A8 and the ponding epimer, which can be separated by chromatography. Further details are given in the experimental section. ysis of the chiral directing group in the chiral alcohol A8 to give the chiral amino l A9 can be accomplished with a mineral acid, e.g. sulfuric acid or particular hydrochloric acid in a solvent such as an ether, e.g. 1,4-dioxane or more particular THF, at temperatures between 0 °C and 50 °C, particular at 23 °C.

The chiral aminooxazines of formula A10 can be prepared by reaction of the chiral amino alcohols of formula A9 with cyanogen bromide in a solvent such as an l, particular ethanol, at temperatures between 23 °C and 100 °C, particular at 80 °C.

Protection of the amino group in chiral compounds of a A10, to produce 2- chloropyridines of a A11 can be performed with triarylmethyl chlorides, such as triphenylmethyl chloride ), p-methoxyphenyldiphenylmethyl chloride (MMTr-Cl), di(pmethoxyphenyl )phenylmethyl de (DMTr-Cl) or tri(p-methoxyphenyl)methyl chloride (TMTr-Cl), particular DMTr-Cl, under basic conditions, e.g. in the presence of an amine, such as ylamine or diisopropylethylamine, in a chlorinated solvent, such as dichloromethane or chloroform, at temperatures n 0 °C and ambient temperature. 2-Chloropyridines of a A11 can be reacted with ammonia equivalents, such as benzophenone imine, in the presence of a suitable transition metal catalyst, such as bis(dibenzylideneacetone)palladium (0) ((dba)2Pd) or tris(dibenzylideneacetone)dipalladium (0) ((dba)3Pd2)), and a suitable ligand, such as rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (rac- BINAP), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (X-PHOS) or 2-di-tert- hosphino-2',4',6'-triisopropylbiphenyl (t-Bu X-PHOS), in the presence of a base, such as sodium tert-butoxide, potassium phosphate or cesium carbonate, in a suitable solvent, such as toluene or 1,4-dioxane, under an inert atmosphere, such as nitrogen or argon, at temperatures between 80 and 110 °C, to produce nds of formula A12.

Deprotection of both amino groups in compounds of formula A12 can be achieved by a one-pot ure by first reacting it with a strong organic acid, such as trifluoroacetic acid, in chlorinated solvents, such as dichloromethane or chloroform, under anhydrous ions at temperatures between 0 °C and ambient temperature to cleave the roup. Then the addition of water or aqueous hydrochloric acid to cleave the benzophenone imine and reaction at ambient temperature produces chiral diamines of formula A13.

The selective protection of the amino group of the 2-aminoxazine residue in diamines of formula A13 to produce compounds of general formula A14, can be performed by reaction with di-tert-butyl dicarbonate under basic conditions, e.g. in the presence of an amine, such as ylamine or diisopropylethylamine, in a solvent, such as tetrahydrofuran or dichloromethane, at temperatures between 0 to 40 °C, particular at ambient temperature.

Amide coupling of 2-aminopyridines of formula A14 and ylic acids of formula R2- CO2H to give amides of formula A15 can be effected with condensating agents, such as O- (benzotriazolyl)-N,N,N’,N’-tetramethyluronium.-hexafluorophosphate (HBTU) or O-(7- azabenzotriazolyl)- N,N,N’,N’-tetramethyluronium-hexafluorophosphate (HATU), in the presence of an amine, such as triethylamine or diisopropylethylamine, in a solvent, such as dichloromethane, acetonitrile or N,N-dimthylformamide, at temperatures between 0 °C and ambient ature.

The cleavage of the protecting tert-butoxy carbonyl groups in compounds of formula A15 to produce compounds of general formula I’ can be effected by acid, such as trifluoroacetic acid, in inert solvents, such as romethane, at temperatures between 0 °C and ambient ature.

B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 Ia-1' Scheme 2: Alternative synthesis of compounds Ia-1’ Alternatively the nds of formula I may be prepared in accordance with scheme 2.

Non-commercial aryl ketones of l a B3 can be synthesized from the silyl protected ne B2 prepared from pyridine B1 by reaction with a strong base, e.g. LDA and an alkylchlorosilane, preferably triethylchlorosilane in an inert aprotic solvents such as tetrahydrofuran or diethyl ether. The protected ne B2 can then be d again with a strong base, e.g. LDA and an amide, e.g. an acetamide for R3 = Me, preferably N,N- dimethylacetamide, in an inert aprotic solvents such as tetrahydrofuran or diethyl ether to give the desired aryl ketone B3.

Sulfinyl imines of formula B4 can be ed in analogy to T.P. Tang & J.A. Ellman, J.

Org. Chem. 1999, 64, 12, by sation of an aryl ketone of formula B3 and a sulfinamide, e.g. an alkyl sulfinamide, most particularly (R)-tert-butylsulfinamide or (S)-tert-butylsulfinamide, in the presence of a Lewis acid such as e.g. a titanium(IV)alkoxide, more particularly titanium(IV)ethoxide, in a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran.

The conversion of sulfinyl imines of formula B4 to sulfinamide esters of formula B5 proceeds stereoselectively by the chiral directing group as described by Tang & Ellman. The yl imines of formula B4 can be reacted in a Reformatsky reaction with a zinc enolate, generated from an alkyl acetate substituted by halogen, e.g. particularly ethyl bromoacetate (R4 = H) and ethyl bromofluoroacetate (R4 = F), and activated zinc powder at ambient to elevated temperature, particularly at 23 to 60 °C, in a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran, optionally in presence of a copper(I) salt, preferably copper(I) chloride.

Alternatively, the sulfinyl imines of formula B4 can be reacted with a titanium e generated from e.g. an alkyl acetate, preferably methyl acetate, LDA and chlorotriisopropoxytitanium at low temperature, preferably at –78 °C in a t such as an ether, e.g. diethyl ether or more preferably THF to give B5.

The conversion of the sulfinamide esters of formula B5 to the ester of formula B6 can be effected with tetrabutylammonium fluoride or preferably potassium fluoride in the presence of an acid e.g. acetic acid in an ether or an amide preferably in a mixture of THF and dimethylformamide at ambient to ed ature, particularly at 23 to 40 °C.

Aldehydes of formula B7 can be prepared by the reduction of ethyl esters of formula B6 with an alkali hydride, e.g. lithium aluminum hydride in presence of diethylamine or sodium dihydrobis(2-methoxyethoxy)aluminate (Red-Al), preferably with diisobutylaluminum hydride (DIBAH) in an inert solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran, or in a chlorinated solvent, such as dichloromethane, at atures between – 78 °C and ambient temperature.

Alternatively, the aldehydes of formula B7 can be prepared by the reduction of ethyl esters of formula B6 to the corresponding alcohols with an alkali hydride, e.g. lithium aluminum e or preferably lithium borohydride in an inert solvent such as an ether, e.g. diethyl ether or more particularly ydrofuran, at temperatures between 0 °C and ambient temperature.

The resulting alcohol can be oxidized to the des of formula B7 by various methods known to someone skilled in the art. DMSO based oxidations, such as the Swern-Moffat oxidation using DMSO, oxalyl chloride and an amine base such as triethylamine or diisopropylethylamine or the Parikh-Doering oxidation using DMSO, sulfur trioxide-pyridine-complex and an amine base such as triethylamine or diisopropylethylamine are particular methods. Another methods is the use of alent iodine reagents, like e.g. the Dess-Martin periodinane in a chlorinated solvent such as dichloromethane at ambient temperature.

Trimethylsilylethers of formula B8 can be obtained by the reaction of aldehydes of formula B7 with a oromethylating agent, ably trifluoromethyltrimethylsilane (Ruppert-Prakash reagent), in presence of tetrabutylammonium fluoride or preferably tetramethylammonium fluoride in a solvent such as an ether, e.g. l ether or more particularly tetrahydrofuran, at temperatures between –10 °C and ambient temperature.

Hydrolysis of the chiral directing group and the trimethylsilylether of formula B8 to give aminoalcohols of formula B9 can be accomplished with a mineral acid, e.g. sulfuric acid or particularly hloric acid, in a solvent such as an ether, e.g. diethyl ether, tetrahydrofuran or more particularly 1,4-dioxane.

Aminooxazines of formula B10 (R, R’= H) can be prepared by reaction of aminoalcohols of formula B9 with cyanogen bromide in a solvent such as an alcohol, particularly ethanol.

The protection of the amino group of the 2-aminoxazine residue of formula B10 to produce compounds of general formula B11, can be performed by on with di-tert-butyl onate under basic conditions, e.g. in the presence of an amine, such as triethylamine or diisopropylethylamine, in a solvent, such as tetrahydrofuran or dichloromethane, at temperatures between 0 to 40 °C, particular at ambient temperature.

Alternatively the compounds of general a B11 can be prepared by the ing sequence: first, aminoalcohols of a B9 are reacted with an isothiocyanate such as benzoylisothiocyanate (BzNCS) in ts such as ethyl acetate, tetrahydrofuran or acetonitrile at temperatures between 0 °C and 80 °C, preferably 23 °C, affords the thiourea alcohols; second, the thiourea alcohols are cyclized to the N-benzoylated oxazines of formula B10 (R = H, R’ = Bz) by ation through on with a carbodiimide, like e.g. dicyclohexylcarbodiimide, diisopropylcarbodiimide or N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC·HCl), preferably EDC·HCl, in solvents such as ethyl acetate, tetrahydrofuran or acetonitrile, preferably acetonitrile, at temperatures between 23 °C and 100 °C, ably 80 °C; third, the switch of protecting groups from the N-benzoylated oxazines of formula B10 (R = H, R’ = Bz) to the N-tert-butoxycarbonylated oxazines of formula B11 can be achieved in a two step procedure by first on with di-tert-butyldicarbonate (Boc2O) in the presence of an amine base such as triethylamine or N-ethyl-N,N-diisopropylamine, in a solvent such as dichlormethane, tetrahydrofuran or acetonitrile, at temperatures between 0 °C and 40 °C, preferably 23 °C, to give the doubly ed e of formula B10 (R = Boc, R’ = Bz), and second selective l of the benzoyl group by reaction of the doubly acylated oxazine of formula B10 (R = Boc, R’ = Bz) with an amine phile, like e.g. diethylamine, dimethylamine or ammonia, preferably ammonia, in a solvent such as dichloromethane or tetrahydrofuran, preferably tetrahydrofuran, at temperatures n 0 °C and 40 °C, preferably 23 °C.

The conversion of the bromo group in formula B11 to the amine group in formula B12 can be performed by reaction with an azide, in particular sodium azide and a cooper (I) halide in particular copper (I) iodide in the presence of rbate and an alkyl-1,2-diamine in particular trans-N,N'-dimethylcyclohexane-1,2-diamine in a protic solvent such as an l in particular ethanol and water at ed temperature preferably approximately 70 °C.

The coupling of the aromatic amine B12 with carboxylic acids to give amides of formula B13 can be effected with T3P in an aprotic solvent such as EtOAc at ambient temperature; or alternatively the carboxylic acids can be activated by using reagents such as oxalyl de or 1- chloro-N,N,2-trimethylpropenylamine (Ghosez’s reagent, CAS-no. 261893) in a chlorinated solvent such as dichloromethane at 0 °C followed by reaction with the aromatic amine B12 in the presence of an amine base such as triethylamine or diisopropylethylamine at 0 °C to ambient temperature.

The cleavage of the protecting tert-butoxy carbonyl groups in compounds of formula B13 to e compounds of general formula I that are of formula Ia-1’ can be effected by acid, such as trifluoroacetic acid, in inert solvents, such as dichloromethane, at temperatures between 0 °C and ambient temperature.

The corresponding pharmaceutically acceptable salts with acids can be obtained by standard methods known to the person skilled in the art, e.g. by dissolving the compound of formula I in a suitable t such as e.g. dioxane or tetrahydrofuran and adding an appropriate amount of the corresponding acid. The products can usually be isolated by filtration or by tography. The conversion of a compound of a I into a pharmaceutically acceptable salt with a base can be carried out by treatment of such a compound with such a base. One possible method to form such a salt is e.g. by on of 1/n equivalents of a basic salt such as e.g. M(OH)n, wherein M = metal or ammonium cation and n = number of ide , to a solution of the compound in a suitable solvent (e.g. ethanol, ethanol-water mixture, tetrahydrofuran-water mixture) and to remove the solvent by evaporation or lyophilisation.

Particular salts are hydrochloride, e and trifluoroacetate. A specific salt is trifluoroacetate.

Insofar as their preparation is not described in the examples, the compounds of formula I as well as all intermediate products can be prepared according to analogous methods or according to the methods set forth herein. Starting materials are commercially available, known in the art or can be prepared by methods known in the art or in y thereto.

It will be appreciated that the compounds of general formula I in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.

Pharmacological Tests The compounds of formula I and their pharmaceutically acceptable salts possess valuable pharmacological properties. It has been found that the nds of the present ion are associated with inhibition of BACE1 activity. The compounds were investigated in accordance with the test given hereinafter.

Cellular A-lowering assay: The Abeta 40 AlphaLISA Assay can be used. The HEK293 APP cells were seeded in 96 well iter plates in cell e medium (Iscove’s, plus 10% (v/v) fetal bovine serum, llin/streptomycin ) to about 80% confluency and the compounds were added at a 3x concentration in 1/3 volume of e medium ( final DMSO concentration was kept at 1 % v/v).

After 18-20 hrs incubation at 37°C and 5% CO2 in a humidified incubator, the e supernatants were harvested for the determination of A 40 concentrations using Perkin-Elmer Human Amyloid beta 1-40 ( high specificity ) Kit ( Cat# AL275C ).

In a Perkin-Elmer White Optiplate-384 ( Cat# 6007290 ), 2ul culture supernatants were combined with 2l of a 10X AlphaLISA Anti-hA Acceptor beads + Biotinylated Antibody Anti-A 1-40 Mix ( 50 µg/mL / 5nM ). After 1 hour room temperature incubation, 16l of a 1.25 X preparation of Streptavidin (SA) Donor beads (25µg/mL ) were added and incubated for 30 minutes in the Dark. Light Emission at 615 nm was then recorded using EnVision-Alpha Reader.

Levels of A 40 in the culture supernatants were calculated as percentage of m signal (cells treated with 1% DMSO without inhibitor). The IC50 value were calculated using the Excel XLfit software.

BACE1 Exam. Structure cell act. A40 IC50 [nM] 1 0.0034 2 0.0305 3 0.0396 4 0.3214 0.039 BACE1 Exam. ure cell act. A40 IC50 [nM] 6 0.2235 7 0.0368 8 0.1749 9 0.286 0.1887 11 0.062 BACE1 Exam. Structure cell act. A40 IC50 [nM] 12 0.027 13 0.067 Table 1: IC50 value Pharmaceutical itions The compounds of formula I and the pharmaceutically acceptable salts can be used as therapeutically active substances, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The compounds of formula I and the pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives f, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatin capsules. Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually ed in the case of soft gelatin capsules.

Suitable carriers for the tion of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

The pharmaceutical preparations can, er, contain pharmaceutically acceptable ary substances such as preservatives, solubilizers, stabilizers, wetting agents, fiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, s, masking agents or antioxidants. They can also contain still other therapeutically valuable substances. ments containing a compound of formula I or a ceutically acceptable salt thereof and a therapeutically inert carrier are also provided by the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.

The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a nd of general a I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in on, the upper limit can also be exceeded when this is found to be indicated.

The following examples illustrate the present invention without ng it, but serve merely as representative thereof. The pharmaceutical preparations conveniently contain about 1- 500 mg, particularly 1-100 mg, of a compound of formula I. Examples of itions according to the ion are: e A Tablets of the following composition are manufactured in the usual manner: ingredient mg/tablet 25 100 500 Compound of formula I 5 25 100 500 Lactose Anhydrous DTG 125 105 30 150 Sta-Rx 1500 6 6 6 60 Microcrystalline Cellulose 30 30 30 450 Magnesium te 1 1 1 1 Total 167 167 167 831 Table 2: possible tablet composition Manufacturing Procedure 1. Mix ingredients 1, 2, 3 and 4 and granulate with purified water. 2. Dry the granules at 50°C. 3. Pass the granules through suitable milling equipment. 4. Add ingredient 5 and mix for three minutes; compress on a suitable press.

Example B-1 Capsules of the following composition are manufactured: ingredient mg/capsule 25 100 500 Compound of formula I 5 25 100 500 s Lactose 159 123 148 - Corn Starch 25 35 40 70 Talk 10 15 10 25 Magnesium Stearate 1 2 2 5 Total 200 200 300 600 Table 3: possible capsule ient composition Manufacturing Procedure 1. Mix ingredients 1, 2 and 3 in a le mixer for 30 minutes. 2. Add ingredients 4 and 5 and mix for 3 minutes. 3. Fill into a suitable capsule.

The compound of formula I, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine. The mixture is ed to the mixer; the talc is added thereto and mixed thoroughly. The mixture is filled by machine into suitable capsules, e.g. hard gelatin capsules.

Example B-2 Soft Gelatin Capsules of the following composition are manufactured: ingredient mg/capsule Compound of formula I 5 Yellow wax 8 Hydrogenated Soya bean oil 8 Partially hydrogenated plant oils 34 Soya bean oil 110 Total 165 Table 4: possible soft gelatin capsule ient composition ingredient mg/capsule Gelatin 75 Glycerol 85 % 32 Karion 83 8 (dry ) Titan dioxide 0.4 Iron oxide yellow 1.1 Total 116.5 Table 5: possible soft gelatin capsule composition Manufacturing Procedure The compound of formula I is dissolved in a warm g of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.

Example C Suppositories of the following composition are manufactured: ingredient p.

Compound of a I 15 itory mass 1285 Total 1300 Table 6: possible suppository composition Manufacturing Procedure The suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45°C. Thereupon, the finely powdered compound of formula I is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository moulds of suitable size, left to cool; the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.

Example D Injection solutions of the ing composition are manufactured: ingredient mg/injection on. nd of formula I 3 Polyethylene Glycol 400 150 acetic acid q.s. ad pH 5.0 water for injection solutions ad 1.0 ml Table 7: possible injection on composition Manufacturing Procedure The compound of formula I is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part). The pH is adjusted to 5.0 by acetic acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate e and ized.

Example E Sachets of the following ition are manufactured: ingredient mg/sachet Compound of formula I 50 Lactose, fine powder 1015 Microcrystalline cellulose (AVICEL PH 102) 1400 Sodium carboxymethyl cellulose 14 Polyvinylpyrrolidon K 30 10 Magnesium stearate 10 Flavoring additives 1 Total 2500 Table 8: possible sachet ition Manufacturing ure The compound of formula I is mixed with lactose, microcrystalline cellulose and sodium ymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water. The granulate is mixed with magnesium stearate and the ing additives and filled into sachets.

Experimental Part The following examples are provided for illustration of the invention. They should not be considered as limiting the scope of the invention, but merely as being representative thereof.

General Abbreviations: Boc = tert-Butoxycarbonyl, DCM = romethane, EDC∙HCl = N-(3- dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride, EtOAc = Ethyl acetate, HCl = hydrogen chloride, HPLC = high performance liquid chromatography, LDA = lithium diisopropylamide, MS = mass spectrum, THF = tetrahydrofuran, and T3P = 2,4,6-Tripropyl- 1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide.

NMR: 1H NMR spectra were recorded on a Bruker AC-300 spectrometer at 25 °C with TMS (tetramethylsilane) or residual 1H of the given deuterated solvents as internal standards.

MS: Mass spectra (MS) were measured either with ion spray ve or negative (ISP or ISN) method on a Perkin-Elmer SCIEX API 300 or with electron impact method (EI, 70 eV) on a Finnigan MAT SSQ 7000 spectrometer.

LC-MS (ESI, positive or negative ion) data were recorded on Waters UPLC-MS Systems equipped with Waters Acquity, a CTC PAL auto sampler and a Waters SQD single quadrupole mass spectrometer using ES ionization modes (positive and/or negative). The separation was achieved on a Zorbax Eclipse Plus C18 1,7 µm 2.1×30 mm column at 50 °C; A = 0.01% formic acid in water, B = acetonitrile at flow 1; nt: 0 min 3% B, 0.2 min 3% B, 2 min 97% B, 1.7 min 97% B, 2.0 min 97% B. The injection volume was 2 µL. MS (ESI, positive or negative ion): FIA (flow injection analysis)-MS were ed on an AppliedBiosystem API150 mass spectrometer. Sample introduction was made with a CTC PAL auto sampler and a Shimadzu LC- 10ADVP Pump. The samples were directly d to the ESI source of the mass spectrometer with a flow 50µL/min of a mixture of acetonitrile and 10 mM ammonium acetate (1:1) without a column. The injection volume was 2 µL Synthesis of intermediates A2 A2a: 6-Chlorofluoro-N-methoxy-N-methylpicolinamide To a magnetically stirred suspension of commercially available 6-chlorofluoropicolinic acid o. 8844942) (25 g, 142 mmol, Eq: 1.00) in dichloromethane (430 ml) and N,N- dimethylformamide (100 ml) at room ature was added N,O-dimethylhydroxylamine hydrochloride (22.2 g, 228 mmol, Eq: 1.6), N-methylmorpholine (23.0 g, 25.1 ml, 228 mmol, Eq: 1.6) and DMAP (1.74 g, 14.2 mmol, Eq: 0.1), cooled to 0° C, added 1-ethyl(3- dimethylaminopropyl)carbodiimid hydrochloride (EDC·HCl) (32.8 g, 171 mmol, Eq: 1.2) and the mixture was allowed to reach ambient temperature over night. After stirring at room temperature for 16 hours the e was poured into 1 M HCl, extracted with DCM, washed with sat. NaHCO3-sol., the organic layer was dried over Na2SO4. l of the solvent in vacuum left a brown liquid (34.2g). The crude material was purified by flash chromatography (silica gel, 100 g, 0% to 30% EtOAc in heptane) to give the product, which was triturated with heptane to give the rofluoro-N-methoxy-N-methylpicolinamide (29.23 g, 134 mmol, 93.9 % yield) as white solid. MS (ISP): m/z = 219.4 [M+H]+ and 221.4 [M+2+H]+.

Synthesis of intermediates A3 A3a: 1-(6-Chlorofluoropyridinyl)ethanone To a solution of 6-chlorofluoro-N-methoxy-N-methylpicolinamide (27.04 g, 124 mmol, Eq: 1.00) in tetrahydrofuran (500 ml) at 0 °C was dropwise added methylmagnesium e (3.2 M in 2-methyl-THF) (58.0 ml, 186 mmol, Eq: 1.5) and the mixture was stirred at room ature for 2 hours. Poured into 3 M HCl, extracted with EtOAc, the organic layer was dried over . Removal of the solvent in vacuum and drying in HV gave the 1 -(6-chloro fluoropyridinyl)ethanone (20.86 g, 120 mmol, 97.2 % yield) as a light yellow solid. MS (ISP): m/z = 174.3 [M+H]+ and 176.3 [M+2+H]+.

Synthesis of intermediates A4 A4a: (R,E)-N-(1-(6-Chlorofluoropyridinyl)ethylidene)methylpropane sulfinamide 1-(6-Chlorofluoropyridinyl)ethanone (22.6 g, 130 mmol, Eq: 1.00), (R) methylpropanesulfinamide (17.4 g, 143 mmol, Eq: 1.1) and titanium(IV) ethoxide (44.6 g, 41.3 ml, 195 mmol, Eq: 1.5) were dissolved in tetrahydrofuran (250 ml) and the mixture heated to 75 °C and stirred at this temperature over night. The mixture was cooled to 23 °C, poured onto sat. NH4Cl-sol., filtered through celite, the solid was washed with ethyl acetate, the te layers were separated, the organic layer was washed with sat. -sol. and brine, dried over Na2SO4. Removal of the solvent left a dark orange solid which was first purified by a short silicagel column tion to remove residual titanium salts, then by column chromatography (silica gel, 100 g, 0% to 50% ethyl acetate in heptane) to give the (R,E)-N-(1-(6-chloro fluoropyridinyl)ethylidene)methylpropanesulfinamide (32.15 g, 116 mmol, 89.2 % yield) as an orange oil. MS (ISP): m/z = 277.4 [M+H]+ and 279.4 [M+2+H]+.

Synthesis of intermediates A5 A5a: (S)-Ethyl 3-(6-chlorofluoropyridinyl)((R)-1,1- dimethylethylsulfinamido)butanoate Activated zinc (11.3 g, 173 mmol, Eq: 3.0) and copper (I) chloride (5.72 g, 57.8 mmol, Eq: 1.00) were suspended in tetrahydrofuran (100 ml) and heated to reflux for 20 min. Cooled to 20 °C, then a solution of ethyl 2-bromoacetate (24.1 g, 16.0 ml, 145 mmol, Eq: 2.5) in tetrahydrofuran (40.0 ml) was added dropwis and stirring was continued for additional 15 min. A solution of (R,E)-N-(1-(6-chlorofluoropyridinyl)ethylidene)methylpropane sulfinamide (16 g, 57.8 mmol, Eq: 1.00) in tetrahydrofuran (40.0 ml) was then added dropwise n 25 °C to 30 °C. Stirring was continued at 23 °C for 1 hour. Then ethanol (4.79 g, 6.08 ml, 104 mmol, Eq: 1.8) was added under ice cooling, filtered all solids off and extracted the filtrate twice with ethyl acetate and sat. NH4Cl-sol. The ed organic layers were washed with water and brine, dried over Na2SO4, filtered and evaporated. The residue was tographed with (100 g SiO2, Flashmaster) 0 - 50% EtOAc in heptane to give (S)-ethyl 3- (6-chlorofluoropyridinyl)((R)-1,1-dimethylethylsulfinamido)butanoate (11.57 g, 31.7 mmol, 54.9 % yield) as a yellow oil. MS (ISP): m/z = 365.4 [M+H]+ and 367.4 [M+2+H]+.

Synthesis of intermediates A6 A6a: (R)-N-((S)(6-Chlorofluoropyridinyl)hydroxybutanyl) methylpropanesulfinamide To a solution of (S)-ethyl 3-(6-chlorofluoropyridinyl)((R)-1,1- dimethylethylsulfinamido)butanoate (11.57 g, 31.7 mmol, Eq: 1.00) in tetrahydrofuran (167 ml) at 0 °C was added lithium borohydride (2 M in THF) (23.8 ml, 47.6 mmol, Eq: 1.5), followed by EtOH (1.46 g, 1.85 ml, 31.7 mmol, Eq: 1.00) and the mixture was stirred at room temperature for 1 hour. Poured into sat NH4Cl-sol., extracted with ethyl acetate, the organic layer was dried over . l of the solvent in vacuum left a brown oil which was ed by chromatography (silica gel, 100 g, 0% to 100% ethyl acetate in heptane) to give the (R)-N-((S)- 2-(6-chlorofluoropyridinyl)hydroxybutanyl)methylpropanesulfinamide (8.85 g, 27.4 mmol, 86.5 % yield) as a yellow oil. MS (ISP): m/z = 323.4 [M+H]+ and 325.4 [M+2+H]+.

Synthesis of intermediates A7 A7a: (R)-N-((S)(6-Chlorofluoropyridinyl)oxobutanyl)methylpropane- 2-sulfinamide To a solution of (R)-N-((S)(6-chlorofluoropyridinyl)hydroxybutanyl) methylpropanesulfinamide (3.22 g, 9.97 mmol, Eq: 1.00) in DMSO (20 ml) and triethylamine (6.06 g, 8.34 ml, 59.8 mmol, Eq: 6.0) was added sulfur trioxide-pyridine complex (4.76 g, 29.9 mmol, Eq: 3.0) at 15 °C. The mixture was stirred for 2 hours at 23 °C. Ice water and 100 ml of sat. NaCl-sol. were added to the reaction mixture, stirred for 10 min, and then extracted twice with ethyl acetate. The organic layers were washed with water and brine, dried over Na2SO4, filtered and evaporated to give a yellow oil. The residue was chromatographed (silica gel, 50 g, 0-80% ethyl e in heptane) to give (R)-N-((S)(6-chlorofluoropyridinyl) oxobutanyl)methylpropanesulfinamide (2.96 g, 9.23 mmol, 92.5 % yield) as a light yellow oil. MS (ISP): m/z = 321.5 [M+H]+ and 323.5 [M+2+H]+.

Synthesis of ediates A8 A8a: (R)-N-((2S,4S)(6-Chlorofluoropyridinyl)-5,5,5-trifluoro hydroxypentanyl)methylpropanesulfinamide and (R)-N-((2S,4R)(6-chloro fluoropyridinyl)-5,5,5-trifluorohydroxypentanyl)methylpropanesulfinamide To a solution of (R)-N-((S)(6-chlorofluoropyridinyl)oxobutanyl) propanesulfinamide (2.96 g, 9.23 mmol, Eq: 1.00) in tetrahydrofuran (50 ml) was added at 0 °C (trifluoromethyl)trimethylsilane (1.97 g, 2.04 ml, 13.8 mmol, Eq: 1.5) dropwise.

Then was added tetramethylammonium fluoride (172 mg, 1.85 mmol, Eq: 0.2) at 0 °C and the brown solution was stirred at 0 °C for 10 min, d the ice bath, the solution was allowed to reach room temperature and ng was continued for 2 hours. Then tetrabutylammonium fluoride (1 M in THF) (10.1 ml, 10.1 mmol, Eq: 1.1) was added dropwise and the mixure was stirred at ambient temperature for another 2 hours. Poured into sat. NaHCO3-sol. and ice, extracted with ethyl e, washed the c layers with brine, dried over Na2SO4 and filtered off. Removal of solvent in vacuum left a light yellow oil, which was purified by flash chromatography (silica gel, 50 g, 0-80% ethyl acetate in heptane) which left (R)-N-((2S,4S) (6-chlorofluoropyridinyl)-5,5,5-trifluorohydroxypentanyl)methylpropane amide (710 mg, 1.82 mmol, 19.7 % yield; less polar isomer) and (R)-N-((2S,4R)(6- chlorofluoropyridinyl)-5,5,5-trifluorohydroxypentanyl)methylpropane sulfinamide (580 mg, 1.48 mmol, 16.1 % yield; more polar isomer), both as brown oils. MS (ISP): m/z = 391.5 [M+H]+ and 393.5 ]+.

Synthesis of intermediates A9 A9a: (2S,4S)Amino(6-chlorofluoropyridinyl)-1,1,1-trifluoropentanol To a solution of (R)-N-((2S,4S)(6-chlorofluoropyridinyl)-5,5,5-trifluoro hydroxypentanyl)methylpropanesulfinamide (710 mg, 1.82 mmol, Eq: 1.00) in tetrahydrofuran was added at ambient temperature conc. HCl (37% in water) (537 mg, 448 µl, .45 mmol, Eq: 3.0). The brown reaction solution was stirred at 23 °C for 2 hours. Poured into sat. NaHCO3-sol., extracted with ethyl acetate, washed organic layer with brine, dried over Na2SO4. l of the solvent in vacuum left a light brown oil which was purified by chromatography (silica gel, 10 g, 0-50% ethyl acetate in heptane) to give (2S,4S)amino(6- chlorofluoropyridinyl)-1,1,1-trifluoropentanol (264 mg, 921 µmol, 50.7 % yield) as a brown oil. MS (ISP): m/z = 287.4 [M+H]+ and 289.5 [M+2+H]+.

Synthesis of intermediates A10 A10a: (4S,6S)(6-Chlorofluoropyridinyl)methyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinamine To a solution of (2S,4S)amino(6-chlorofluoropyridinyl)-1,1,1-trifluoropentan- 2-ol (262 mg, 914 µmol, Eq: 1.00) in l (5 ml) was added under argon at ambient temperature sodium bicarbonate (30.7 mg, 366 µmol, Eq: 0.4) and cyanogen bromide (290 mg, 2.74 mmol, Eq: 3.00). The brown reaction solution was d at 80 °C in a sealed tube for 20 hours. Poured into ice water and sat. NaHCO3-sol., then extracted with ethyl acetate. The organic layer was dried over Na2SO4, filtered and evaporated. The residue was purified by chromatography (silica gel, 10 g, 0-80% ethyl acetate in e) to give (4S,6S)(6-chloro fluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinamine (170 mg, 436 µmol, 47.7 % yield) as a light brown solid. MS (ISP): m/z = 312.5 [M+H]+ and 314.5 [M+2+H]+.

Synthesis of intermediates A11 A11a: (4S,6S)-N-(bis(4-methoxyphenyl)(phenyl)methyl)(6-chlorofluoropyridin- 2-yl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinamine To a solution of (4S,6S)(6-chlorofluoropyridinyl)methyl(trifluoromethyl)- ,6-dihydro-4H-1,3-oxazinamine (170 mg, 436 µmol, Eq: 1.00) in dichloromethane (10 ml) and diisopropylethylamine (113 mg, 152 µl, 873 µmol, Eq: 2.0) was added at ambient temperature 4,4'-dimethoxytrityl de (222 mg, 655 µmol, Eq: 1.5). The reaction solution was stirred at 23 °C for 4 hours. The reaction mixture was washed with water and brine. The organic layer was dried over Na2SO4, filtered and ated. The residue was purified by chromatography (silica gel, 10 g, 0 - 50% ethyl acetate in heptane) to give (4S,6S)-N-(bis(4- yphenyl)(phenyl)methyl)(6-chlorofluoropyridinyl)methyl(trifluoromethyl)- ,6-dihydro-4H-1,3-oxazinamine (163 mg, 265 µmol, 60.8 % yield) as an off-white foam. MS (ISP): m/z = 615.1 [M+H]+ and 617.2 [M+2+H]+.

Synthesis of intermediates A12 A12a: (4S,6S)-N-(bis(4-methoxyphenyl)(phenyl)methyl)(6- (diphenylmethyleneamino)fluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro- 4H-1,3-oxazinamine Under argon in a sealed tube were added to a solution of (4S,6S)-N-(bis(4- methoxyphenyl)(phenyl)methyl)(6-chlorofluoropyridinyl)methyl(trifluoromethyl)- ,6-dihydro-4H-1,3-oxazinamine (160 mg, 261 µmol, Eq: 1.00) in toluene (3 ml) sodium tertbutoxide (75.1 mg, 782 µmol, Eq: 3.00), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos) (18.6 mg, 39.1 µmol, Eq: 0.15) and tris(dibenzylideneacetone)dipalladium(0) (11.9 mg, 13.0 µmol, Eq: 0.05). henone imine (94.4 mg, 87.5 µl, 521 µmol, Eq: 2.00) was added finally via syringe. The tube was sealed under argon and the mixture was stirred at 85 °C for 3.5 hours. After cooling to ambient temperature the brown solution was extracted with ethyl acetate and water. The organic layer was washed with brine, dried over Na2SO4, filtered and evaporated to give a brown oil. The residue was purified by chromatography (silica gel, 10 g, 0-50% ethyl acetate in e) to give (4S,6S)-N-(bis(4-methoxyphenyl)(phenyl)methyl)(6- nylmethyleneamino)fluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H- 1,3-oxazinamine (123 mg, 162 µmol, 62.2 % yield) as a light yellow foam. MS (ISP): m/z = 759.3 [M+H]+.

Synthesis of intermediates A13 A13a: (4S,6S)(6-Aminofluoropyridinyl)methyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinamine To a solution of (4S,6S)-N-(bis(4-methoxyphenyl)(phenyl)methyl)(6- (diphenylmethyleneamino)fluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H- 1,3-oxazinamine (122 mg, 161 µmol, Eq: 1.00) in dichloromethane (10 ml) was added at ambient temperature trifluoroacetic acid (1.83 g, 1.24 ml, 16.1 mmol, Eq: 100). The orange reaction solution was stirred at 23 °C for 1 hour and then evaporated. The residue was ved in dioxane (20 ml) and 1 N HCl (3.22 ml, 3.22 mmol, Eq: 20) was added. Stirring was continued at 23 °C for 3 hours. Poured into 1 M Na2CO3, ted twice with ethyl acetate, washed the ed organic layers with water and brine, dried over Na2SO4 and filtered. Removal of the solvent in vacuum left a brown oil which was purified by chromatography (silica gel, 5 g; ethyl acetate/MeOH 8:1) to give )(6-aminofluoropyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinamine (35 mg, 120 µmol, 74.5 % yield) as an off-white foam. MS (ISP): m/z = 293.5 [M+H]+. sis of intermediates A14 A14a: tert-Butyl (4S,6S)(6-aminofluoropyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate To a solution of (4S,6S)(6-aminofluoropyridinyl)methyl(trifluoromethyl)- ,6-dihydro-4H-1,3-oxazinamine (32 mg, 110 µmol, Eq: 1.00) in dichloromethane (1 ml) and diisopropylethylamine (19.8 mg, 26.8 µl, 153 µmol, Eq: 1.4) was added at rt di-tert-butyl dicarbonate (Boc2O) (28.7 mg, 131 µmol, Eq: 1.2). The clear, colourless reaction solution was stirred at 23 °C for 20 hours. All volatiles were d in vacuum and the residue was purified by chromatography (silica gel, 10 g; ethyl acetate/MeOH 8:1) to give tert-butyl (4S,6S)(6- aminofluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin ylcarbamate (41.3 mg, 105 µmol, 96.1 % yield) as a white foam. MS (ISP): m/z = 393.4 [M+H]+.

Synthesis of intermediates A15 A15a: tert-Butyl )(6-(5-cyanopicolinamido)fluoropyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate 5-Cyanopicolinic acid (19.4 mg, 131 µmol, Eq: 1.30) was dissolved in dichloromethane (0.8 ml) and DMF (0.4 ml), then ropylethylamine (39.0 mg, 52.7 µl, 302 µmol, Eq: 3.00) and (dimethylamino)-N,N-dimethyl(3H-[1,2,3]triazolo[4,5-b]pyridinyloxy)methaniminium hexafluorophosphate (HATU) (57.4 mg, 151 µmol, Eq: 1.50) were added at ambient temperature.

The resulting yellow solution was stirred for 10 min then a solution of tert-butyl (4S,6S)(6- aminofluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin ylcarbamate (39.5 mg, 101 µmol, Eq: 1.00) in dichloromethane (0.8 ml) was added. The brown reaction solution was stirred at 23 °C for 16 hours. The reaction e was poured into ice cold sat. NaHCO3 solution and extracted twice with dichloromethane. The organic layers were washed with brine, dried over , filtered and evaporated. The residue was purified by chromatography (silica gel, 5 g, 0-50% ethyl acetate in heptane) to give tert-butyl (4S,6S)(6- (5-cyanopicolinamido)fluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3- oxazinylcarbamate (16 mg,30.6 µmol, 30.4 % yield) as a colourless oil. MS (ISP): m/z = 523.6 [M+H]+.

Synthesis of the intermediate pyridine B2b (R2 = Cl): 2-Bromochloro (triethylsilyl)pyridine To a solution of diisopropylamine (10.6 g) in THF (170 ml) was added at –20 °C n-butyl lithium (1.6 M in hexane, 65.6 ml) over 30 min and the solution was allowed to warm to 0 °C and stirring was continued for 30 min. The solution was cooled again to –78 °C and treated with a solution of 2-bromochloropyridine (19.2 g) in THF (30 ml) over 15 min and ng was ued for 1 h. To the dark brown solution was added triethylchlorosilane (16.6 g) over 3 min, the mixture was warm to –20 °C and was poured into a mixture of aqueous HCl (1 M, 110 ml) and half-saturated aqueous NH4Cl (110 ml) and ted with t-butylmethyl ether (300 ml). The c layer was washed with brine, dried, evaporated and the residue purified by flash chromatography (SiO2, gradient of EtOAc in heptane, 0 to 20% EtOAc) to give the title compound (30.7 g, 86%) as a pale yellow liquid. MS (ESI): m/z = 306.3, 308.3, 310.3 [M+H]+.

Synthesis of the ediate ketone B3b (R2 = Cl): 1-(6-Bromochloro (triethylsilyl)pyridinyl)ethanone To a solution of diisopropylamine (17.2 g) in THF (400 ml) was added at –20 °C n-butyl lithium (1.6 M in hexane, 106 ml) over 30 min and the solution was allowed to warm to 0 °C and stirring was continued for 30 min. The solution was cooled again to –78 °C and treated with a solution of 2-bromochloro(triethylsilyl)pyridine B2b (40.0 g) in THF (40 ml) over 15 min and stirring was continued for 15 min. To the dark red solution was added N,N- dimethylacetamide (14.8 g) over 2 min and stirring was continued for 20 min. The mixture was warm to –40 °C, poured into a mixture of s HCl (1 M, 200 ml) and brine (200 ml) and extracted with lmethyl ether. The c layer was washed with brine, dried and evaporated to give the crude title compound as a brown oil (41.5 g).

Synthesis of the intermediate sulfinyl imines B4 B4a (R2 = F): (R,E)-N-(1-(6-Bromofluoro(triethylsilyl)pyridinyl)ethylidene) methylpropanesulfinamide To a solution of 1-(6-bromofluoro(triethylsilyl)pyridinyl)ethanone, prepared according to Badiger, S. et al., int. patent application WO 2012095469A1, (8.13 g) in THF (59 ml) was added subsequently at 22 °C (R)-(+)-tert-butylsulfinamide (3.26 g) and titanium(IV)ethoxide (11.2 g) and the solution was stirred at 60 °C for 6 h. The e was cooled to 22 °C, treated with brine, the suspension was stirred for 10 min and filtered over dicalite. The layers were separated, the aqueous layer was extracted with ethyl acetate, the combined organic layers were washed with water, dried and evaporated. The residue was purified by flash chromatography (SiO2, n-heptane/EtOAc, 5:1) to give the title compound (7.5 g, 70%) as a yellow oil. MS (ESI): m/z = 435.3, 437.3 [M+H]+.

B4b (R2 = Cl): (R,E)-N-(1-(6-Bromochloro(triethylsilyl)pyridinyl)ethylidene)- 2-methylpropanesulfinamide Crude 1-(6-bromochloro(triethylsilyl)pyridinyl)ethanone B3b (41.5 g) was reacted with (R)-(+)-tert-butylsulfinamide in analogy to the preparation of nd B4a to give after cation by flash chromatography (SiO2, gradient of EtOAc in e, 0 - 10% EtOAc) the title compound (18.0 g) as an orange oil. MS (ESI): m/z = 451.1, 453.1, 455.1 [M+H]+.

Synthesis of the intermediate sulfinamide esters B5 B5a (R2 = F): (S)-Ethyl 3-(6-bromofluoro(triethylsilyl)pyridinyl)((R)-1,1- dimethylethylsulfinamido)butanoate To a solution of ropylamide (9.41 g) in THF (325 ml) was added at –20 °C nbutyllithium (1.6 M solution in hexane, 58.1 ml) and stirring was continued at 0 °C for 30 min.

The solution was cooled to –78 °C, treated with ethyl acetate (8.19 g) keeping the ature below -70 °C and stirring was continued at –78 °C for 30 min. A solution of chlorotriisopropoxytitanium (24.2 g) in THF (65 ml) was added and stirring was continued at – 78 °C for 30 min. The mixture was treated with a solution of (R,E)-N-(1-(6-bromofluoro (triethylsilyl)pyridinyl)ethylidene)methylpropanesulfinamide B4a (13.5 g) in THF (65 ml) and stirring was continued at –78 °C for 1 h. The mixture was quenched with saturated aqueous NH4Cl solution, filtered over dicalite, the organic layer was washed with water, dried, ated and the residue purified by flash chromatography (SiO2, gradient of n-heptane/EtOAc (5 to 45% EtOAc) to give the title compound (11.5 g, 71%) as a pale yellow oil. MS (ESI): m/z = 523.6, 525.6 [M+H]+.

B5b (R2 = Cl): hyl 3-(6-bromochloro(triethylsilyl)pyridinyl)((R)-1,1- dimethylethylsulfinamido)butanoate N-(1-(6-Bromochloro(triethylsilyl)pyridinyl)ethylidene)methylpropane- 2-sulfinamide B4b (14.0 g) was reacted with ethyl acetate in analogy to the preparation of compound B5a to give after purification by flash chromatography (SiO2, gradient of EtOAc in heptane, 0 - 50% EtOAc) the title compound (6.1 g) as an orange oil. MS (ESI): m/z = 539.2, 541.2, 543.2 [M+H]+. A second fraction contained the starting material (7.44 g).

B5c (R2, R4 = F): (2R,3R)-Ethyl 3-(6-bromofluoropyridinyl)((R)-1,1- dimethylethylsulfinamido)fluorobutanoate ted zinc (3.33 g, 51.0 mmol) was suspended in tetrahydrofuran (90 ml) and heated to reflux. A solution of ethyl 2-bromofluoroacetate (9.43 g, 6.03 ml, 51.0 mmol) and N- (1-(6-bromofluoro(triethylsilyl)pyridinyl)ethylidene)methylpropanesulfinamide (11.1 g, 25.5 mmol) in tetrahydrofuran (50 ml) was added drop wise and stirred an additional hour at 70 °C. Removed from oilbath and the reaction was quenched by drop wise addition of ethanol (2 ml), filtered through Celite and extracted with EtOAc and sat NH4Cl-sol., dried over Na2SO4, filtered and evaporated. The crude material was purified by flash chromatography (silica gel, 50 g, 0% to 50% EtOAc in heptane) to give the (2R,3R)-ethyl 3-(6-bromofluoro (triethylsilyl)pyridinyl)((R)-1,1-dimethylethylsulfinamido)fluorobutanoate (9.9 g, 18.3 mmol, 71.7 % yield) as a yellow oil. MS (ESI): m/z = 541.6, 543.6 [M+H]+.

Synthesis of the ediate esters B6 B6a (R2 = F): (S)-Ethyl 3-(6-bromofluoropyridinyl)((R)-1,1- dimethylethylsulfinamido)butanoate To a solution of (S)-ethyl romofluoro(triethylsilyl)pyridinyl)((R)-1,1- dimethylethylsulfinamido)butanoate B5a (11.5 g) in THF (100 ml) was added uently at 22 °C acetic acid (2.64 g), KF (2.55 g) and DMF (100 ml) and stirring was continued at 22 °C for 2 h and at 40 °C for 30 min. The mixture was partitioned between EtOAc (600 ml) and aqueous saturated NaHCO3-sol. (600 ml), the organic layer was washed with brine, dried and evaporated (50 °C, 2 mbar) to give the crude title compound (9.27 g) as a pale yellow oil. MS (ESI): m/z = 409.5, 411.5 [M+H]+.

B6b (R2 = Cl): (S)-Ethyl 3-(6-bromochloropyridinyl)((R)-1,1- dimethylethylsulfinamido)butanoate hyl 3-(6-bromochloro(triethylsilyl)pyridinyl)((R)-1,1- dimethylethylsulfinamido)butanoate B5b (3.7 g) was reacted with KF in analogy to the preparation of compound B6a to give the crude title compound (3.05 g) as an light brown oil.

MS (ESI): m/z = 425.1, 427.1, 429.1 [M+H]+.

B6c (R2, R4 = F): (2R,3R)-Ethyl 3-(6-bromofluoropyridinyl)((R)-1,1- dimethylethylsulfinamido)fluorobutanoate To a solution of (2R,3R)-ethyl 3-(6-bromofluoro(triethylsilyl)pyridinyl)((R)- 1,1-dimethylethylsulfinamido)fluorobutanoate B5c (10.5 g, 19.4 mmol) in N,N- dimethylformamide (105 ml) and tetrahydrofuran (105 ml) at room temperature was added dry potassium fluoride (2.25 g, 38.8 mmol) and acetic acid (1.16 g, 1.11 ml, 19.4 mmol,) and the mixture was stirred at room temperature for 3 hours. Poured into sat NaHCO3-sol., extracted with EtOAc, the organic layer was dried over Na2SO4. Removal of the t in vacuum left the (2R,3R)-ethyl 3-(6-bromofluoropyridinyl)((R)-1,1-dimethylethylsulfinamido) fluorobutanoate (6 g, 14.0 mmol, 72.4 % yield) as a light yellow oil. MS (ESI): m/z = 427.5, 429.5 [M+H]+.

Synthesis of the intermediate aldehydes B7 B7a (R2 = F): ((S)(6-Bromofluoropyridinyl)oxobutanyl) methylpropanesulfinamide To a solution of crude (S)-ethyl 3-(6-bromofluoropyridinyl)((R)-1,1- dimethylethylsulfinamido)butanoate B6a (8.8 g) in dichloromethane (220 ml) was added at –78 °C diisobutylaluminum hydride (1 M in toluene, 49 ml) over 15 min and ng was continued for 1 h. The mixture was treated with aqueous saturated NH4Cl, warmed to 23 °C, filtered through te, the organic layer was dried, evaporated and the residue purified by flash chromatography (SiO2, gradient of EtOAc in heptane, 5 to 100% EtOAc) to give the title (4.0 g, 51%) as a colorless oil. MS (ESI): m/z = 365.3, 367.3 [M+H]+.

B7b (R2 = Cl): (R)-N-((S)(6-bromochloropyridinyl)oxobutanyl) methylpropanesulfinamide Crude (S)-ethyl 3-(6-bromochloropyridinyl)((R)-1,1- dimethylethylsulfinamido)butanoate B6b (3.0 g) was d with diisobutylaluminum hydride in y to the preparation of compound B7a to give after flash chromatography (SiO2, gradient of EtOAc in heptane, 0 to 50% EtOAc) the title compound (2.69 g, 45%) as a pale yellow oil. MS (ESI): m/z = 381.1, 383.1, 385.1 [M+H]+.

B7c (R2, R4 = F): (R)-N-((2R,3R)(6-bromofluoropyridinyl)fluoro oxobutanyl)methylpropanesulfinamide Step 1: (R)-N-((2R,3R)(6-bromofluoropyridinyl)fluorohydroxybutan yl)methylpropanesulfinamide To a solution of )-ethyl 3-(6-bromofluoropyridinyl)((R)-1,1- ylethylsulfinamido)fluorobutanoate B6c (4.13 g, 9.67 mmol) and ethanol (445 mg, 564 µl, 9.67 mmol, Eq: 1.00) in tetrahydrofuran (26.6 ml) at 0 °C was dropwise added a 2 M on of lithium dride in THF (7.25 ml, 14.5 mmol) and the mixture was stirred at room temperature for 2 hours. Poured into sat NH4Cl-sol., extracted with EtOAc, the organic layer was dried over Na2SO4. Removal of the solvent in vacuum give the (R) R,3R)(6-bromo fluoropyridinyl)fluorohydroxybutanyl)methylpropanesulfinamide (3.65 g, 9.47 mmol, 98.0 % yield) as a white foam. MS (ESI): m/z = 385.2, 387.2 [M+H]+.

Step 2: To a solution of the product from step 1 (R)-N-((2R,3R)(6-bromo fluoropyridinyl)fluorohydroxybutanyl)methylpropanesulfinamide (3.65 g, 9.47 mmol) in dichloromethane (114 ml) at 0 °C was added Dess-Martin periodinane (4.82 g, 11.4 mmol) and the mixture was stirred at room temperature for 3 hours. Added 300 ml ether and stirred for 20 minutes, filtered off the solid and washed with ether, extracted with sat NaHCO3- sol., the organic layer was dried over Na2SO4. Removal of the solvent in vacuum left a white solid, which was triturated with DCM, filtered off the solid and evaporated the organic layer totally to give 3.7 g of a yellow foam. The crude material was purified by flash chromatography (silica gel, 50 g, 0% to 70% EtOAc in heptane) to give the (R)-N-((2R,3R)(6-bromo fluoropyridinyl)fluorooxobutanyl)methylpropanesulfinamide (2.36 g, 6.16 mmol, 65.0 % yield) as a white solid. MS (ESI): m/z = 383.1, 385.1 [M+H]+.

Synthesis of the intermediate trimethylsilyl ethers B8 B8a (R2 = F): (R)-N-((2S,4S)(6-Bromofluoropyridinyl)-5,5,5-trifluoro (trimethylsilyloxy)pentanyl)methylpropanesulfinamide To a solution of (R)-N-((S)(6-bromofluoropyridinyl)oxobutanyl) methylpropanesulfinamide B7a (2.0 g) in THF (40 ml) was subsequently added at -28 °C (trifluoromethyl)trimethylsilane (1.56 g) and tetramethylammonium fluoride (51.2 mg) and stirring of the yellow solution was continued for 1 h. A further portion of tetramethylammonium fluoride (564 mg) was added and stirred was ued at -20 °C for 1 h. The mixture was ioned between aqueous saturated NaHCO3 (100 ml) and EtOAc (200 ml), the organic layer was washed with brine, dried, evaporated and the residue purified by flash chromatography (SiO2, gradient of AcOEt in heptane, 17-25% EtOAc) to give an inseparable 1:1 e of the title nd and its deprotected alcohol (1.10 g) as a yellow oil. MS (ESI): m/z = 507.3, 509.3 [M+H]+.

The slower eluting fraction contained the epimeric alcohol, (R)-N-((2S,4R)(6-bromo fluoropyridinyl)-5,5,5-trifluorohydroxypentanyl)methylpropanesulfinamide (0.40 g) as a yellow oil. MS (ESI): m/z = 435.3, 437.3 [M+H]+.

B8b (R2 = Cl): (R)-N-((2S,4S)(6-Bromochloropyridinyl)-5,5,5-trifluoro thylsilyloxy)pentanyl)methylpropanesulfinamide (R)-N-((S)(6-Bromochloropyridinyl)oxobutanyl)methylpropane sulfinamide B7b (1.10 g) was reacted with (trifluoromethyl)trimethylsilane in analogy to the preparation of compound B8a to give after flash chromatography (SiO2, gradient of EtOAc in heptane, 15 to 35% EtOAc) the faster g undesired epimer, (R)-N-((2S,4R)(6-bromo chloropyridinyl)-5,5,5-trifluoro(trimethylsilyloxy)pentanyl)methylpropane sulfinamide (165 mg, 11%) as a colorless oil. MS (ESI): m/z = 523.0, 525.0, 527.0 [M+H]+.

The slower eluting fraction ned the title compound (0.67 g, 44%) as a colorless oil.

MS (ESI): m/z = 523.0, 525.0, 527.0 [M+H]+.

B8c (R2, R4 = F): (R)-N-((2R,3R,4S)(6-Bromofluoropyridinyl)-3,5,5,5- tetrafluoro(trimethylsilyloxy)pentanyl)methylpropanesulfinamide and B8d (R2, R4 = F) (R)-N-((2R,3R,4R)(6-Bromofluoropyridinyl)-3,5,5,5-tetrafluoro (trimethylsilyloxy)pentanyl)methylpropanesulfinamide To a solution of (R)-N-((2R,3R)(6-bromofluoropyridinyl)fluorooxobutan yl)methylpropanesulfinamide B7c (2.047 g, 5.34 mmol) in ydrofuran (30.7 ml) at –20 °C was added (trifluoromethyl)trimethylsilane (1.52 g, 1.71 ml, 10.7 mmol, Eq: 2) followed by tetrabutylammonium fluoride (TBAF, 1 M in THF) (534 µl, 534 µmol) and the mixture was d at –20 °C for 2 hours. Poured into sat NH4Cl-sol., extracted with EtOAc, the organic layer was dried over Na2SO4. Removal of the solvent in vacuum left a yellow oil. The crude al was purified by flash chromatography (silica gel, 20 g, 0% to 50% EtOAc in heptane) to give (R)-N-((2R,3R,4R)(6-bromofluoropyridinyl)-3,5,5,5-tetrafluoro (trimethylsilyloxy)pentanyl)methylpropanesulfinamide B8d (432 mg, 822 µmol, 15.4 % yield) as the faster eluting isomer and (R)-N-((2R,3R,4S)(6-bromofluoropyridinyl)- 3,5,5,5-tetrafluoro(trimethylsilyloxy)pentanyl)methylpropanesulfinamide B8c (495 mg, 942 µmol, 17.6 % yield) as the slower eluting . Additional (R)-N-((2R,3R,4R)(6- bromofluoropyridinyl)-3,5,5,5-tetrafluorohydroxypentanyl)methylpropane sulfinamide (376 mg, 830 µmol, 15.5 % yield) was also isolated.

B8c: MS (ESI): m/z = 525.1, 527.1 [M+H]+; B8d: MS (ESI): m/z = 525.1, 527.1 [M+H]+.

Synthesis of the intermediate aminoalcohols B9 B9a (R2 = F): (2S,4S)Amino(6-bromofluoropyridinyl)-1,1,1- trifluoropentanol To a 1:1-mixture of (R)-N-((2S,4S)(6-bromofluoropyridinyl)-5,5,5-trifluoro thylsilyloxy)pentanyl)methylpropanesulfinamide B8a and its deprotected alcohol (1.07 g) in dioxane (38 ml) was added at 22 °C hydrochloric acid (4 M in dioxane, 2.5 ml) and ng of the solution was continued for 1 h. The mixture was evaporated, the residue partitioned between EtOAc and ice water, the pH of the aqueous layer was adjusted to 8 with aqueous saturated NaHCO3 and ted with EtOAc. The organic layer was dried and evaporated to give the crude title compound (0.70 g) as a pale yellow oil. MS (ESI): m/z = 331.3, 333.3 [M+H]+.

B9b (R2 = Cl): (2S,4S)Amino(6-bromochloropyridinyl)-1,1,1- trifluoropentanol (R)-N-((2S,4S)(6-Bromochloropyridinyl)-5,5,5-trifluoro (trimethylsilyloxy)pentanyl)methylpropanesulfinamide B8b (0.56 g) was deprotected with hydrochloric acid in analogy to the preparation of compound B9a to give the crude title compound (345 mg, 93%) as a colorless oil. MS (ESI): m/z = 347.4, 349.4, 351.4 [M+H]+.

B9c (R2, R4 = F): (2S,3R,4R)Amino(6-bromofluoropyridinyl)-1,1,1,3- tetrafluoropentanol To a solution of (R)-N-((2R,3R,4S)(6-bromofluoropyridinyl)-3,5,5,5-tetrafluoro- methylsilyloxy)pentanyl)methylpropanesulfinamide B8c (495 mg, 942 µmol) in tetrahydrofuran (19 ml) at room temperature was added conc. HCl (495 mg, 309 µl, 3.77 mmol) and the mixture was stirred at room temperature for 2 hours. Poured into sat. NaHCO3-sol., extracted with EtOAc, the organic layer was dried over Na2SO4. Removal of the t in vacuum left a yellow oil. The crude material was ed by flash chromatography (silica gel, 10 g, 0% to 40% EtOAc in heptane) to give the (2S,3R,4R)amino(6-bromofluoropyridin yl)-1,1,1,3-tetrafluoropentanol (95 mg, 272 µmol, 28.9 % yield) as a colorless solid. MS (ESI): m/z = 349.1, 351.1 [M+H]+.

B9d (R2, R4 = F): (2R,3R,4R)Amino(6-bromofluoropyridinyl)-1,1,1,3- tetrafluoropentanol To a solution of (R)-N-((2R,3R,4R)(6-bromofluoropyridinyl)-3,5,5,5-tetrafluoro- 4-hydroxypentanyl)methylpropanesulfinamide B8d (680 mg, 1.5 mmol) in tetrahydrofuran (5 ml) at 0 °C was dropwise added HCl (4 M in dioxane) (375 µl, 1.5 mmol) and the mixture was stirred at room temperature for 2 hours. Poured into sat NaHCO3-sol., extracted with EtOAc, the organic layer was dried over Na2SO4. Removal of the solvent in vacuum left a yellow oil. The crude material was ed by flash chromatography (silica gel, 20 g, 0% to 50% EtOAc in heptane) to give 373 mg white where the chiral auxiliary was moved to the hydroxyl group. Dissolved in MeOH (10 ml), cooled to 0 °C, added excess 3 M NaOH excess and stirred for 30 minutes. Extracted with water and EtOAc, dried the organic layer over Na2SO4, filtered off and evaporated totally. The crude material was purified by flash chromatography (silica gel, g, EtOAc in e, 0 to 50%) to give (2R,3R,4R)amino(6-bromofluoropyridin yl)-1,1,1,3-tetrafluoropentanol (373 mg, 1.07 mmol, 71.2 % yield) as a white solid. MS (ESI): m/z = 349.1, 351.1 [M+H]+.

Synthesis of the intermediate xazines B10 B10a (R2 = F): (4S,6S)(6-Bromofluoropyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinamine To a on of (2S,4S)amino(6-bromofluoropyridinyl)-1,1,1-trifluoropentan- 2-ol B9a (670 mg) in ethanol (14 ml) was added at 22 °C a solution of Br-CN in acetonitrile (5 M, 0.61 ml) and the mixture was heated in a sealed tube to 85 °C for 15 h. The mixture was evaporated, the residue ioned between half saturated aqueous Na2CO3 and EtOAc, The organic layer was dried, evaporated and the residue purified by flash chromatography (SiO2, gradient of EtOAc in heptane, 20 to 80% EtOAc) to give the title compound (255 mg, 35%) as a pale yellow solid. MS (ESI): m/z = 356.4, 358.4 .

B10b (R2 = Cl): (4S,6S)(6-Bromochloropyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinamine (2S,4S)Amino(6-bromochloropyridinyl)-1,1,1-trifluoropentanol B9b (335 mg) was reacted with Br-CN in analogy to the preparation of compound B10a to give the title compound (148 mg, 41%) as a pale yellow oil. MS (ESI): m/z = 372.0, 374.0, 376,0 [M+H]+.

Synthesis of the ediate Boc-aminooxazines B11 B11a (R2 = F): tert-Butyl (4S,6S)(6-bromofluoropyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate To a solution of (4S,6S)(6-bromofluoropyridinyl)methyl(trifluoromethyl)- 5,6-dihydro-4H-1,3-oxazinamine B10a (245 mg) in dichloromethane (5 ml) was subsequently added at 22 °C N,N-diisopropylethylamine (124 mg) and Boc-anhydride (180 mg) and stirring was continued for 15 h. The mixture was evaporated and the residue purified by flash tography (SiO2, gradient of EtOAc in heptane, 5 to 100% EtOAc) to give the title compound (276 mg, 88%) as a colorless solid. MS (ESI): m/z = 456.3, 458.3 [M+H]+.

B11b (R2 = Cl): tert-Butyl (4S,6S)(6-bromochloropyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate (4S,6S)(6-Bromochloropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H- 1,3-oxazinamine B10b (27 mg) was reacted with Boc-anhydride in analogy to the preparation of compound B11a to give after flash chromatography (SiO2, nt of EtOAc in heptane, 0 to % EtOAc) the title compound (27 mg, 79%) as a white solid. MS (ESI): m/z = 472.2, 474.2, 476.2 [M+H]+.

B11c (R2, R4 = F): tert-Butyl (4R,5R,6S)(6-bromofluoropyridinyl)fluoro methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate Step 1: N-((2R,3R,4S)(6-Bromofluoropyridinyl)-3,5,5,5-tetrafluoro hydroxypentanylcarbamothioyl)benzamide To a solution of (2S,3R,4R)amino(6-bromofluoropyridinyl)-1,1,1,3- tetrafluoropentanol B9c (145 mg, 415 µmol) in tetrahydrofuran (14 ml) at room temperature was added benzoyl isothiocyanate (67.8 mg, 55.9 µl, 415 µmol) and the mixture was stirred at room temperature for 16 hours. All les were removed in vacuum and the crude material was purified by flash chromatography a gel, 10 g, 0% to 40% EtOAc in heptane) to give the N-((2R,3R,4S)(6-bromofluoropyridinyl)-3,5,5,5-tetrafluorohydroxypentan ylcarbamothioyl)benzamide (203 mg, 396 µmol, 95.4 % yield) as a light yellow foam. MS (ESI): m/z = 512.1, 514.1 [M+H]+.

Step 2: N-((4R,5R,6S)(6-Bromofluoropyridinyl)fluoromethyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)benzamide To a on of N-((2R,3R,4S)(6-bromofluoropyridinyl)-3,5,5,5-tetrafluoro hydroxypentanylcarbamothioyl)benzamide (from step 1 above) (203 mg, 396 µmol) in acetonitrile (4 ml) at room temperature was added EDC∙HCl (114 mg, 594 µmol) and the mixture was stirred at 80 °C for 2 hours. The crude material was purified by flash chromatography (silica gel, 20 g, 0% to 30% EtOAc in heptane) to give the ,5R,6S)(6- bromofluoropyridinyl)fluoromethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin- 2-yl)benzamide (157 mg, 328 µmol, 82.9 % yield) as a white foam. MS (ESI): m/z = 478.2, 480.2 [M+H]+.

Step 3: tert-Butyl benzoyl((4R,5R,6S)(6-bromofluoropyridinyl)fluoro methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)carbamate To a solution of N-((4R,5R,6S)(6-bromofluoropyridinyl)fluoromethyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)benzamide (from step 2 above) (157 mg, 328 µmol) in ydrofuran (15.4 ml) at room temperature was added di-tert-butyl dicarbonate ) (78.8 mg, 83.8 µl, 361 µmol) and ylamine (36.5 mg, 50.3 µl, 361 µmol) followed by 4-dimethylaminopyridine (8.02 mg, 65.7 µmol) and the mixture was stirred at room temperature for 30 minutes. Removal of the solvent in vacuum at ambient temperature left a light yellow oil. The crude material was purified by flash chromatography (silica gel, 20 g, 0% to 35% EtOAc in heptane) to give the tert-butyl benzoyl((4R,5R,6S)(6-bromofluoropyridinyl)- -fluoromethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)carbamate (129 mg, 223 µmol, 67.9 % yield) as a white foam. MS (ESI): m/z = 578.2, 580.2 [M+H]+.

Step 4: tert-Butyl (4R,5R,6S)(6-bromofluoropyridinyl)fluoromethyl uoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate To a solution of tert-butyl benzoyl((4R,5R,6S)(6-bromofluoropyridinyl)fluoro- 4-methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)carbamate (from step 3 above) (129 mg, 223 µmol) in methanol (10 ml) at 0 °C was added 7 M ammonia in MeOH (3.19 ml, 22.3 mmol) and the mixture was stirred at room temperature for 30 minutes. Removal of the solvent in vacuum at ambient ature left a yellow oil. The crude material was purified by flash chromatography a gel, 20 g, 0% to 60% EtOAc in heptane) to give the tert-butyl (4R,5R,6S)(6-bromofluoropyridinyl)fluoromethyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinylcarbamate (75 mg, 158 µmol, 70.9 % yield) as a white solid. MS (ESI): m/z = 474.1, 476.1 [M+H]+.

B11d (R2, R4 = F): tert-Butyl (4R,5R,6R)(6-bromofluoropyridinyl)fluoro methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate Step 1: N-((2R,3R,4R)(6-Bromofluoropyridinyl)-3,5,5,5-tetrafluoro hydroxypentanylcarbamothioyl)benzamide To a solution of (2S,3R,4R)amino(6-bromofluoropyridinyl)-1,1,1,3- tetrafluoropentanol B9d (373 mg, 1.07 mmol) in tetrahydrofuran (35 ml) at room temperature was added benzoyl isothiocyanate (174 mg, 144 µl, 1.07 mmol) and the mixture was stirred at room ature for 16 hours. All volatiles were removed in vacuum and the crude material was ed by flash chromatography (silica gel, 20 g, 0% to 40% EtOAc in heptane) to give the N-((2R,3R,4R)(6-bromofluoropyridinyl)-3,5,5,5-tetrafluorohydroxypentan ylcarbamothioyl)benzamide (473 mg, 923 µmol, 86.4 % yield) as a light yellow foam. MS (ESI): m/z = 512.1, 514.1 [M+H]+.

Step 2: N-((4R,5R,6R)(6-Bromofluoropyridinyl)fluoromethyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)benzamide To a solution of ,3R,4S)(6-bromofluoropyridinyl)-3,5,5,5-tetrafluoro hydroxypentanylcarbamothioyl)benzamide (from step 1 above) (473 mg, 923 µmol) in acetonitrile (10 ml) at room temperature was added EDC∙HCl (265 mg, 1.38 mmol) and the mixture was stirred at 80 °C for 2 hours. The crude material was purified by flash chromatography (silica gel, 20 g, 0% to 30% EtOAc in heptane) to give the N-((4R,5R,6R)(6- bromofluoropyridinyl)fluoromethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin- 2-yl)benzamide (330 mg, 690 µmol, 74.7 % yield) as a white foam. MS (ESI): m/z = 478.2, 480.2 [M+H]+.

Step 3: utyl benzoyl((4R,5R,6R)(6-bromofluoropyridinyl)fluoro methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)carbamate To a on of ,5R,6R)(6-bromofluoropyridinyl)fluoromethyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)benzamide (from step 2 above) (330 mg, 690 µmol) in tetrahydrofuran (32.4 ml) at room temperature was added di-tert-butyl dicarbonate (Boc2O) (166 mg, 176 µl, 759 µmol) and triethylamine (76.8 mg, 106 µl, 759 µmol) followed by 4-dimethylaminopyridine (16.9 mg, 138 µmol) and the mixture was d at room temperature for 3 days. Removal of the solvent in vacuum at ambient temperature left a light yellow oil. The crude al was purified by flash chromatography (silica gel, 20 g, 0% to 35% EtOAc in heptane) to give the tert-butyl benzoyl((4R,5R,6S)(6-bromofluoropyridinyl)fluoro methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)carbamate (399 mg, 690 µmol, 100 % yield) as a white foam. MS (ESI): m/z = 578.2, 580.2 [M+H]+.

Step 4: tert-Butyl (4R,5R,6S)(6-bromofluoropyridinyl)fluoromethyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate To a solution of tert-butyl l((4R,5R,6R)(6-bromofluoropyridinyl)fluoro- 4-methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)carbamate (from step 3 above) (399 mg, 690 µmol) in methanol (20 ml) at 0 °C was added 7 M ammonia in MeOH (9.86 ml, 69.0 mmol) and the mixture was stirred at room temperature for 30 minutes. Removal of the solvent in vacuum at ambient temperature left a yellow oil. The crude material was purified by flash chromatography (silica gel, 20 g, 0% to 60% EtOAc in e) to give the tert-butyl (4R,5R,6R)(6-bromofluoropyridinyl)fluoromethyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinylcarbamate (237 mg, 500 µmol, 72.4 % yield) as a colorless oil. MS (ESI): m/z = 474.1, 476.1 [M+H]+.

Synthesis of the intermediate Boc-aminopyridine B12 B12a (R2 = F): tert-Butyl (4S,6S)(6-aminofluoropyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate To a solution of tert-butyl (4S,6S)(6-bromofluoropyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B11a (175 mg) in ethanol (5.4 ml) and water (2.4 ml) was subsequently added at 23 °C sodium azide (199 mg), copper (I) iodide (29 mg), sodium L-ascorbate (15.2 mg) and trans-N,N'-dimethylcyclohexane-1,2-diamine (33 mg) and stirring of the light blue on was continued at 70 °C for 1 h. The mixture was partitioned between saturated aqueous NaHCO3 and EtOAc, the organic layer was dried, evaporated and the residue ed by flash chromatography (SiO2, gradient of EtOAc in heptane, 25 to 40% EtOAc) to give the title compound (82 mg, 54%) as a colorless solid. MS (ESI): m/z = 393.5 [M+H]+.

B12b (R2 = Cl): tert-Butyl (4S,6S)(6-aminochloropyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate tert-Butyl )(6-Bromochloropyridinyl)methyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinylcarbamate B11b (25 mg) was reacted with sodium azide in analogy to the preparation of compound B12a to give after flash chromatography (SiO2, gradient of AcOEt in heptane, 10 - 50% EtOAc) the title compound (9 mg, 42%) as a colorless foam. MS (ESI): m/z = 409.2, 411.2 [M+H]+.

B12c (R2, R4 = F): tert-Butyl ,6S)(6-aminofluoropyridinyl)fluoro methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate To a solution of tert-butyl (4R,5R,6S)(6-bromofluoropyridinyl)fluoro (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B11c (75 mg, 158 µmol) in dioxane (3.00 ml) and water (1.00 ml) at room temperature was added sodium azide (82.3 mg, 1.27 mmol), sodium L-ascorbate (6.27 mg, 31.6 µmol), trans-N,N'-dimethylcyclohexane-1,2- diamine (13.5 mg, 15.0 µl, 94.9 µmol) and copper (I) iodide (12.0 mg, 63.3 µmol) after 10 minutes is was dark green-blue, the e was d at 70 °C for 30 s. Added again sodium L-ascorbate (6.27 mg, 31.6 µmol), trans-N,N'-dimethylcyclohexane-1,2-diamine (13.5 mg, 15.0 µl, 94.9 µmol) and copper (I) iodide (12.0 mg, 63.3 µmol) and continued stirring at 70 °C for another 30 minutes. Poured into sat. NaHCO3-sol., extracted with EtOAc, the organic layer was dried over Na2SO4. Removal of the solvent in vacuum left a dark green oil. The crude material was purified by flash chromatography (silica gel, 10 g, 0% to 40% EtOAc in heptane) to give the tert-butyl (4R,5R,6S)(6-aminofluoropyridinyl)fluoromethyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate (29 mg, 70.7 µmol, 44.7 % yield) as a white solid. MS (ESI): m/z = 411.2 [M+H]+.

B12d (R2, R4 = F): tert-Butyl (4R,5R,6R)(6-aminofluoropyridinyl)fluoro methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate To a solution of tert-butyl (4R,5R,6R)(6-bromofluoropyridinyl)fluoro methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B11d (237 mg, 500 µmol) in dioxane (3.00 ml) and water (1.00 ml) at room temperature was added sodium azide (260 mg, 4.00 mmol), sodium rbate (19.8 mg, 100 µmol), trans-N,N'-dimethylcyclohexane-1,2- diamine (42.7 mg, 47.3 µl, 300 µmol) and copper (I) iodide (38.1 mg, 200 µmol) after 10 minutes is was dark blue, the mixture was stirred at 70 °C for 1 hour. Added again sodium L-ascorbate (19.8 mg, 100 µmol), trans-N,N'-dimethylcyclohexane-1,2-diamine (42.7 mg, 47.3 µl, 300 µmol) and copper (I) iodide (38.1 mg, 200 µmol) and continued stirring at 70 °C for another 30 minutes. Poured into sat. NaHCO3-sol., extracted with EtOAc, the organic layer was dried over Na2SO4. Removal of the solvent in vacuum left a dark green oil. The crude material was purified by flash chromatography (silica gel, 10 g, 0% to 40% EtOAc in heptane) to give the tert-butyl ,6R)(6-aminofluoropyridinyl)fluoromethyl(trifluoromethyl)- ,6-dihydro-4H-1,3-oxazinylcarbamate (50 mg, 122 µmol, 24.4 % yield) as a white solid. MS (ESI): m/z = 411.2 [M+H]+.

Synthesis of the intermediate Boc-amides A15 and B13 and deprotected amides I General procedure for the coupling of the Boc-aminopyridines A14 or B12 with the acid to the Boc-amide A15 or B13 T3P-method: To a on of the Boc-aminopyridine A14 or B12 (0.10 mmol) and the acid (0.2 mmol) in EtOAc (1.2 ml) was added at 22 °C T3P (50% in EtOAc, 0.09 ml, 0.15 mmol) and stirring was continued 2 h. A further portion of T3P (0.05 ml, 0.08 mmol) was added and stirring was continued for 2 h. The mixture was ioned between saturated aqueous NaHCO3 and EtOAc, the c layer was dried, evaporated and the residue purified by flash tography (SiO2, gradient of EtOAc in heptane) to give the Boc-amide A15 or B13.

Ghosez’s reagent method: To a suspension of the acid (197 µmol, Eq: 1.5) in dry romethane (1.5 ml) at 0 °C was dropwise added 1-chloro-N,N,2-trimethylpropenylamine (Ghosez’s reagent) (52.8 mg, 395 µmol, Eq: 3) and the mixture was stirred at 0 °C for 1 hour.

This mixture was then added to a solution of the Boc-aminopyridine A14 or B12 (132 µmol, Eq: 1.00) and diisopropylethylamine (51.0 mg, 69.0 µl, 395 µmol, Eq: 3) in dry dichloromethane (1.5 ml) at 0 °C. The ice bath was removed and the mixture was stirred 1 to 16 hour(s) at ambient temperature. ated totally at t temperature und directly purified by flash tography (silica gel, gradient of EtOAc in heptane) to give the Boc-amide A15 or B13.

General procedure for the deprotection of the Boc-amide A15 or B13 to the amide I To a solution of the Boc-amide A15 or B13 (0.04 mmol) in dichloromethane (0.5 ml) was added at 22 °C trifluoroacetic acid (1.2 mmol) and stirring was continued for 16 h. The mixture was evaporated, the residue diluted with EtOAc and evaporated again. The residue was triturated with diethyl ether/pentane, the suspension was filtered and the residue dried to give the amide I.

Alternative workup to obtain the free base: after stirring for 16 h, all volatiles were removed in , the residue was partitioned between EtOAc and sat. NaHCO3-sol., the organic layer was washed with brine and dried over Na2SO4. Filtration and removal of the solvent in vacuum left the crude product which was purified by flash chromatography to give the amide I.

B13a-1 (R2 = F): tert-Butyl (4S,6S)(6-(3-chlorocyanopicolinamido) fluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate tert-Butyl (4S,6S)(6-aminofluoropyridinyl)methyl(trifluoromethyl)-5,6- o-4H-1,3-oxazinylcarbamate B12a (39 mg) was coupled with 3-chlorocyanopyridinecarboxylic acid according to the T3P-method to give after flash chromatography (SiO2, gradient of EtOAc in heptane, 5 to 50% EtOAc) the title compound (17 mg, 30%) as a colorless solid. MS (ESI): m/z = 557.6, 559.6 [M+H]+.

B13a-2 (R2 = F): tert-Butyl (4S,6S)(6-(3-chloro(trifluoromethyl)picolinamido) fluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate tert-Butyl (4S,6S)(6-aminofluoropyridinyl)methyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinylcarbamate B12a (39 mg) was coupled with 3-chloro (trifluoromethyl)pyridinecarboxylic acid according to the T3P-method to give after flash chromatography (SiO2, gradient of EtOAc in heptane, 5 to 50% EtOAc) the title compound (26 mg, 44%) as a colorless solid. MS (ESI): m/z = 600.3, 602.3 [M+H]+.

B13a-3 (R2 = F): tert-Butyl (4S,6S)(3-fluoro(5-methoxypyrazine carboxamido)pyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin ylcarbamate tert-Butyl (4S,6S)(6-aminofluoropyridinyl)methyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinylcarbamate B12a (39 mg) was d with 5-methoxypyrazine carboxylic acid according to the T3P-method to give after flash chromatography (SiO2, gradient of AcOEt in heptane, 5 - 50% EtOAc) the title nd (14 mg, 27%) as an off-white solid.

MS (ESI): m/z = 529.4 [M+H]+.

B13a-4 (R2 = F): tert-Butyl )(6-(5-cyanomethylpicolinamido) pyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate tert-Butyl (4S,6S)(6-aminofluoropyridinyl)methyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinylcarbamate B12a (39 mg) was coupled with 5-cyanomethylpyridinecarboxylic acid according to the T3P-method to give after flash chromatography (SiO2, gradient of EtOAc in heptane, 5 to 50% EtOAc) the title compound (22 mg, 41%) as a colorless foam. MS (ESI): m/z = 537.6 [M+H]+.

B13a-5 (R2 = F): tert-Butyl (4S,6S)(3-fluoro(5-methoxypicolinamido)pyridin yl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate tert-Butyl (4S,6S)(6-aminofluoropyridinyl)methyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinylcarbamate B12a (39 mg) was coupled with 5-methoxypyridine carboxylic acid according to the T3P-method to give after flash chromatography (SiO2, gradient of EtOAc in heptane, 5 to 50% EtOAc) the title compound (16 mg, 30%) as a colorless foam.

MS (ESI): m/z = 528.6 [M+H]+.

B13a-6 (R2 = F): tert-Butyl (4S,6S)(6-(4-chloro(difluoromethyl)-1H-pyrazole carboxamido)fluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3- oxazinylcarbamate utyl )(6-aminofluoropyridinyl)methyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinylcarbamate B12a (39 mg) was d with 4-chloro (difluoromethyl)pyrazolecarboxylic acid, prepared according to H. t et al., J. Med.

Chem. 2013, 56, 3980, according to the T3P-method to give after flash chromatography (SiO2, gradient of EtOAc in heptane, 5 to 50% EtOAc) the title compound (26 mg, 46%) as an offwhite solid. MS (ESI): m/z = 571.5, 573.5 [M+H]+.

B13a-7 (R2 = F): tert-Butyl (4S,6S)(6-(5-(difluoromethyl)pyrazinecarboxamido)- 3-fluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin ylcarbamate tert-Butyl (4S,6S)(6-aminofluoropyridinyl)methyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinylcarbamate B12a (39 mg) was coupled with 5- (difluoromethyl)pyrazinecarboxylic acid, prepared according to WO2009091016, ing to the T3P-method to give after flash tography (SiO2, gradient of EtOAc in heptane, 5 to 50% EtOAc) the title compound (30 mg, 55%) as an colorless foam. MS (ESI): m/z = 549.2 [M+H]+.

B13a-8 (R2 = F): tert-Butyl (4S,6S)(6-(3,5-dichloropicolinamido)fluoropyridin yl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate utyl (4S,6S)(6-aminofluoropyridinyl)methyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinylcarbamate B12a (39 mg) was coupled with 3,5-dichloropyridine carboxylic acid according to the thod to give after flash chromatography (SiO2, gradient of EtOAc in heptane, 5 to 50% EtOAc) the title compound (26 mg, 46%) as an colorless solid.

MS (ESI): m/z = 566.5, 568.5 [M+H]+.

B13a-9 (R2 = F): tert-Butyl (4S,6S)(3-fluoro(5- (fluoromethoxy)picolinamido)pyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H- 1,3-oxazinylcarbamate tert-Butyl (4S,6S)(6-aminofluoropyridinyl)methyl(trifluoromethyl)-5,6- dihydro-4H-1,3-oxazinylcarbamate B12a (39 mg) was coupled with 5- (fluoromethoxy)pyridinecarboxylic acid, prepared according to WO 2009091016, according to the T3P-method to give after flash chromatography (SiO2, gradient of EtOAc in heptane, 5 to 60% EtOAc) the title compound (18 mg, 33%) as an ess solid. MS (ESI): m/z = 546.5 [M+H]+.

B13b (R2 = Cl): tert-Butyl (4S,6S)(3-chloro(5-cyanopicolinamido)pyridinyl) methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate To a solution of 5-cyanopyridinecarboxylic acid (14 mg) in romethane (0.6 ml) and dimethylformamide (0.3 ml) was added subsequently at 22 °C N,N-diisopropylethylamine (29 mg) and HATU (42 mg) and after 15 min tert-butyl (4S,6S)(6-aminochloropyridin yl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B12b (30 mg) and stirring was ued for 4 h. The e was partitioned between saturated aqueous NaHCO3 and dichloromethane, the organic layer was dried, evaporated and the residue purified by flash tography (SiO2, gradient of EtOAc in heptane, 5 to 50% EtOAc) to give the title compound (4 mg, 10%) as a white solid. MS (ESI): m/z = 539.2, 541.2 [M+H]+.

B13c-1 (R2, R4 = F): tert-Butyl (4R,5R,6S)(6-(5-cyanopicolinamido) fluoropyridinyl)fluoromethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin ylcarbamate tert-Butyl (4R,5R,6S)(6-aminofluoropyridinyl)fluoromethyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B12c (29 mg, 70.7 µmol) was coupled with 5-cyanopicolinic acid according to the Ghosez’s reagent-method to give after flash chromatography (SiO2, gradient of EtOAc in heptane, 0 to 45% EtOAc) the title compound (23 mg, 42.6 µmol, 60.2 % yield) as a white foam. MS (ESI): m/z = 541.3 [M+H]+.

B13d-1 (R2, R4 = F): utyl (4R,5R,6R)(6-(5-cyanopicolinamido) fluoropyridinyl)fluoromethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin ylcarbamate tert-Butyl (4R,5R,6R)(6-aminofluoropyridinyl)fluoromethyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B12d (54 mg, 132 µmol) was coupled with 5-cyanopicolinic acid according to the Ghosez’s reagent-method to give after flash tography (SiO2, gradient of EtOAc in heptane, 0 to 45% EtOAc) the title compound (55 mg, 102 µmol, 77.3 % yield) as a white solid. MS (ESI): m/z = 541.2 .

Example 1 N-(6-((4S,6S)aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)- -fluoropyridinyl)cyanopicolinamide To a solution of tert-butyl (4S,6S)(6-(5-cyanopicolinamido)fluoropyridinyl) methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate (16 mg, 30.6 µmol, Eq: 1.00) in dichloromethane (0.5 ml) was added TFA (105 mg, 70.8 µl, 919 µmol, Eq: 30) at 10 °C.

The light yellow reaction solution was stirred at 23 °C for 3 hours. The solvent was evaporated, then basified with ice cold 1 N Na2CO3-sol., stirred for 15 min at 10 °C, then extracted twice with ethyl acetate, washed the combined organic layers with brine, dried over Na2SO4, filtered and ated. The residue was purified by chromatography (silica gel, 5 g, 0-50% ethyl e in heptane, then 0-10% MeOH in ethyl acetate) to give N-(6-((4S,6S)aminomethyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)fluoropyridinyl)cyanopicolinamide (9.5 mg, 22.5 µmol, 73.4 % yield) as a white solid. MS (ISP): m/z = 423.6 [(M+H)+].

Example 2 N-(6-((4S,6S)Aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)- -fluoropyridinyl)chlorocyanopicolinamide tert-Butyl (4S,6S)(6-(3-chlorocyanopicolinamido)fluoropyridinyl)methyl uoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13a (18 mg) was deprotected to give the title compound (14 mg, 76%) as an off-white solid. MS (ESI): m/z = 457.1, 459.1 [M+H]+.

Example 3 N-(6-((4S,6S)Aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)- ropyridinyl)chloro(trifluoromethyl)picolinamide, salt with trifluoroacetic acid tert-Butyl (4S,6S)(6-(3-chloro(trifluoromethyl)picolinamido)fluoropyridinyl) methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13a-2 (26 mg) was deprotected to give the title compound (27 mg, quant.) as a pale yellow solid. MS (ESI): m/z = 500.3, 501.3 [M+H]+.

Example 4 N-(6-((4S,6S)Aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)- -fluoropyridinyl)methoxypyrazinecarboxamide, salt with trifluoroacetic acid tert-Butyl (4S,6S)(3-fluoro(5-methoxypyrazinecarboxamido)pyridinyl) methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13a-3 (14 mg) was deprotected to give the title compound (14 mg, 80%) as an off-white solid. MS (ESI): m/z = 429.6 [M+H]+.

Example 5 N-(6-((4S,6S)Aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)- -fluoropyridinyl)cyanomethylpicolinamide, salt with trifluoroacetic acid tert-Butyl (4S,6S)(6-(5-cyanomethylpicolinamido)fluoropyridinyl)methyl uoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13a-4 (20 mg) was deprotected to give the title compound (21 mg, 78%) as an off-white solid. MS (ESI): m/z = 437.5 [M+H]+.

Example 6 N-(6-((4S,6S)Aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)- 5-fluoropyridinyl)methoxypicolinamide, salt with trifluoroacetic acid tert-Butyl (4S,6S)(3-fluoro(5-methoxypicolinamido)pyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13a-5 (16 mg) was deprotected to give the title compound (9 mg, 55%) as an off-white solid. MS (ESI): m/z = 428.2 [M+H]+.

Example 7 N-(6-((4S,6S)Aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)- -fluoropyridinyl)chloro(difluoromethyl)-1H-pyrazolecarboxamide, salt with trifluoroacetic acid tert-Butyl (4S,6S)(6-(4-chloro(difluoromethyl)-1H-pyrazolecarboxamido) fluoropyridinyl)methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13a-6 (23 mg) was deprotected to give the title nd (14 mg, 59%) as an off-white solid.

MS (ESI): m/z = 471.5, 473.5 [M+H]+.

N-(6-((4S,6S)Aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)- -fluoropyridinyl)(difluoromethyl)pyrazinecarboxamide, salt with trifluoroacetic acid utyl (4S,6S)(6-(5-(difluoromethyl)pyrazinecarboxamido)fluoropyridinyl)- 4-methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13a-7 (21 mg) was deprotected to give the title compound (18 mg, 84%) as an ite solid. MS (ESI): m/z = 449.2 [M+H]+.

Example 9 N-(6-((4S,6S)Aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)- -fluoropyridinyl)-3,5-dichloropicolinamide, salt with trifluoroacetic acid tert-Butyl (4S,6S)(6-(3,5-dichloropicolinamido)fluoropyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13a-8 (26 mg) was deprotected to give the title compound (21 mg, 90%) as a ess solid. MS (ESI): m/z = 466.4, 468.4, 470.4 [M+H]+.

Example 10 N-(6-((4S,6S)Aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)- -fluoropyridinyl)(fluoromethoxy)picolinamide, salt with oroacetic acid tert-Butyl (4S,6S)(3-fluoro(5-(fluoromethoxy)picolinamido)pyridinyl)methyl- 6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13a-9 (16 mg) was deprotected to give the title nd (16 mg, 93%) as an off-white solid. MS (ESI): m/z = 446.5 [M+H]+.

Example 11 N-(6-((4S,6S)Aminomethyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinyl)- -chloropyridinyl)cyanopicolinamide tert-Butyl (4S,6S)(3-chloro(5-cyanopicolinamido)pyridinyl)methyl (trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13b (4 mg) was deprotected with CF3COOH and evaporated. The residue was partitioned between saturated aqueous Na2CO3 and EtOAc, the organic layer was dried, evaporated and the residue purified by flash chromatography (NH2-phase from e, gradient of EtOAc in heptane, 0 to 50% EtOAc) to give the title compound (3 mg, 98%) as a white solid. MS (ESI): m/z = 439.2, 441.2 [M+H]+.

Example 12 N-(6-((4R,5R,6S)Aminofluoromethyl(trifluoromethyl)-5,6-dihydro-4H-1,3- oxazinyl)fluoropyridinyl)cyanopicolinamide tert-Butyl (4R,5R,6S)(6-(5-cyanopicolinamido)fluoropyridinyl)fluoro methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13c-1 (23 mg, 42.6 µmol) was ected and the crude material was purified by flash chromatography (silica gel, 10 g, 0% to 100% EtOAc in heptane) to give the title compound (12 mg, 27.3 µmol, 64.0 % yield) as a white solid. MS (ESI): m/z = 441.2 [M+H]+.

Example 13 (4R,5R,6R)Aminofluoromethyl(trifluoromethyl)-5,6-dihydro-4H-1,3- oxazinyl)fluoropyridinyl)cyanopicolinamide tert-Butyl (4R,5R,6R)(6-(5-cyanopicolinamido)fluoropyridinyl)fluoro methyl(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazinylcarbamate B13d-1 (55 mg, 102 µmol) was deprotected and the crude material was purified by flash chromatography (silica gel, 10 g, 0% to 100% EtOAc in heptane) to give the title compound (30 mg, 68.1 µmol, 66.9 % yield) as a white foam. MS (ESI): m/z = 441.2 [M+H]+.

Claims (15)

Claims

1. A compound of formula I, H N O R5 H N R1 N N R4 wherein 5 R1 is heteroaryl substituted by 1-2 substituents individually selected from amino, cyano, n, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy and C1alkyl; R2 is F; R3 is ; R4 is fluoro; 10 R5 is trifluoromethyl; or pharmaceutically acceptable salts thereof.

2. A compound of formula I, which is of formula Ia-1 H N O CF 2 3 H N R1 N N R4 F Ia-1 wherein 15 R1 is heteroaryl tuted by 1-2 substituents individually selected from amino, cyano, halogen, halogen-C1alkoxy, halogen-C1alkyl, C1alkoxy and C1alkyl; R3 is methyl; R4 is fluoro; or pharmaceutically acceptable salts thereof. 20

3. A compound according to claim 1 or 2, wherein R1 is heteroaryl substituted by 1-2 tuents individually selected from amino and cyano.

4. A compound according to any one of claims 1-3, wherein whenever R1 is heteroaryl it is nyl, 1H-pyrazolyl or pyrazinyl.

5. A compound according to any one of claims 1-4, wherein whenever R1 is heteroaryl it is pyridinyl or nyl.

6. A compound according to any one of claims 1-5, wherein whenever R1 is aryl it is nyl. 5

7. A compound according to any one of claims 1-6, wherein R1 is 3,5-dichloro-pyridinyl, 3- chlorocyano-pyridinyl, 3-chlorotrifluoromethyl-pyridinyl, 4-chloro (difluoromethyl)-1H-pyrazolyl, 5-(difluoromethyl)-pyrazinyl, 5-(fluoromethoxy)pyridinyl, 5-cyanomethyl-pyridinyl, 5-cyano-pyridinyl, 5-methoxy-pyrazinyl or 5-methoxypyridinyl. 10

8. A nd according to any one of claims 1-7, wherein R1 is 5-cyano-pyridineyl.

9. A compound according to any one of claims 1-8, that is selected from the group consisting 15 or a pharmaceutically acceptable salt thereof.

10. A compound of a I according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, for use as a therapeutically active substance, for use as therapeutically active substance for the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated β-amyloid levels and/or β-amyloid 20 oligomers and/or β-amyloid plaques and further deposits or Alzheimer's disease, or for use as therapeutically active nce for the therapeutic and/or prophylactic treatment of amyotrophic lateral sis (ALS), arterial thrombosis, autoimmune/inflammatory diseases, cancer such as breast cancer, cardiovascular diseases such as myocardial tion and stroke, omyositis, Down’s Syndrome, gastrointestinal diseases, 25 Glioblastoma multiforme, Graves Disease, Huntington’s Disease, inclusion body myositis (IBM), inflammatory reactions, Kaposi Sarcoma, Kostmann Disease, lupus erythematosus, macrophagic myofasciitis, le idiopathic arthritis, granulomatous arthritis, ant melanoma, multiple mieloma, rheumatoid arthritis, Sjogren syndrome, erebellar Ataxia 1, SpinoCerebellar Ataxia 7, Whipple’s e or Wilson’s Disease. 5

11. A pharmaceutical composition comprising a compound of a I according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable auxiliary substance.

12. Use of a compound of formula I ing to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the therapeutic and/or 10 prophylactic treatment of Alzheimer's disease.

13. A compound, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-10 substantially as herein bed with reference to any example f.

14. A pharmaceutical composition according to claim 11 substantially as herein described with reference to any example thereof. 15

15. Use according to claim 12 substantially as herein described with reference to any example thereof.